Three stocks to watch as a big annual biotech conference gets underway

147
36
Favorite

Three stocks to watch as a big annual biotech conference gets underway

CNBC2021-05-31

The annual ASCO meeting begins at the end of the week, a conference that has often provided a tailwind for biotech and pharma names. Biotech has been a laggard this year, gaining big in February and ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

147

Report

Comment（36）

Tigger777
·2021-06-01
Diversify the investment in BioNTech stocks
Reply
Like
Report
hmmwvms
·2021-06-01
L&C (like and comment) please. Thank you :)
Reply
2
Report
Fold Replies
- HH浩:
  Reciprocate
  2021-06-01
  Reply
  Report
- hmmwvms:
  Thank you
  2021-06-01
  Reply
  Report
Fartyclown
·2021-06-01
?
Reply
4
Report
Fold Replies
- Fartyclown:
  .
  2021-06-02
  Reply
  Report
- Fartyclown:
  ??
  2021-06-01
  Reply
  Report
- Godskitchen:
  skill
  2021-06-01
  Reply
  Report
ryanlow
·2021-06-01
wow
Reply
3
Report
Fold Replies
- aesemera:
  cheers!
  2021-06-01
  Reply
  Report
- Shadotaiger:
  reply?
  2021-06-01
  Reply
  Report
LiuQY
·2021-06-01
Gooooooooo
Reply
4
Report
Fold Replies
- Singman:
  pls like and comment on me too.
  2021-06-01
  Reply
  Report
- ryanlow:
  wow
  2021-06-01
  Reply
  Report
MrMrsBean
·2021-06-01
[強]
Reply
4
Report
Fold Replies
- WeiChyi:
  K
  2021-06-01
  Reply
  Report
Alannjy
·2021-06-01
Like and comment
Reply
4
Report
Fold Replies
- Mythology:
  ?
  2021-06-01
  Reply
  Report
- CLONGER:
  Done.
  2021-06-01
  Reply
  Report
happymoney
·2021-06-01
Bio
Reply
3
Report
Fold Replies
- happymoney:
  Likey
  2021-06-01
  Reply
  Report
- Alannjy:
  Like and comment
  2021-06-01
  Reply
  Report
Genes
·2021-06-01
Ok
Reply
3
Report
Fold Replies
- Alannjy:
  Like and comment
  2021-06-01
  Reply
  Report
- RAMA:
  LookS Good
  2021-06-01
  Reply
  Report
banchin
·2021-06-01
Please give me comments and like
Reply
3
Report
Fold Replies
- Alannjy:
  Like and comment
  2021-06-01
  Reply
  Report
- Andtendo:
  Ok
  2021-06-01
  Reply
  Report
WWX2020
·2021-06-01
This is odd
Reply
3
Report
Fold Replies
- LiuQY:
  Hiiiii
  2021-06-01
  Reply
  Report
WWX2020
·2021-06-01
Please like
Reply
3
Report
AlexRach
·2021-06-01
Ok
Reply
1
Report
Fold Replies
- LiuQY:
  To the moom
  2021-06-01
  Reply
  Report
chloectf
·2021-06-01
Always interesting to learn about these more niche companies ?
Reply
3
Report
Fold Replies
- yesssuu:
  nice
  2021-06-01
  Reply
  Report
- jaswsf:
  [强] [OK]
  2021-06-01
  Reply
  Report
Dollarvan
·2021-06-01
Like n comment
Reply
4
Report
Fold Replies
- 小小馒头:
  Sure boss!
  2021-06-01
  Reply
  Report
TWKF
·2021-05-31
Yes
Reply
1
Report
chiin
·2021-05-31
Yes
Reply
3
Report
Fold Replies
- chiin:
  ?
  2021-05-31
  Reply
  Report
- AshleyKinson:
  ok
  2021-05-31
  Reply
  Report
AshleyKinson
·2021-05-31
3?
Reply
3
Report
Fold Replies
- chiin:
  Yes itsay
  2021-05-31
  Reply
  Report
tangtkh
·2021-05-31
Watch
Reply
4
Report
Fold Replies
- AshleyKinson:
  what
  2021-05-31
  Reply
  Report
ShashaRenz
·2021-05-31
Like please
Reply
Like
Report

Most Discussed

7x24

All

Terms and Conditions·Privacy Policy

Company: TTMF Limited. Tech supported by Xiangshang Yixin.

Email：uservice@ttm.financial

{"i18n":{"language":"en_US"},"data":{"share":"https://ttm.financial/m/news/1104481164?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2021-05-31 21:48","share_image_url":"https://static.laohu8.com/72bb72e1b84c09fca865c6dcb1bbcd16","id":"1104481164","market":"us","top_or_hot":-1,"title":"Three stocks to watch as a big annual biotech conference gets underway","media":"CNBC","content":"<div>\n<p>The annual ASCO meeting begins at the end of the week, a conference that has often provided a tailwind for biotech and pharma names.\nBiotech has been a laggard this year, gaining big in February and ...</p>\n\n<a href=\"https://www.cnbc.com/2021/05/31/3-stocks-to-watch-as-asco-conference-gets-underway-.html\">Source Link</a>\n\n</div>\n","source":"cnbc_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Three stocks to watch as a big annual biotech conference gets underway</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nThree stocks to watch as a big annual biotech conference gets underway\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-05-31 21:48 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.cnbc.com/2021/05/31/3-stocks-to-watch-as-asco-conference-gets-underway-.html><strong>CNBC</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The annual ASCO meeting begins at the end of the week, a conference that has often provided a tailwind for biotech and pharma names.\nBiotech has been a laggard this year, gaining big in February and ...</p>\n\n<a href=\"https://www.cnbc.com/2021/05/31/3-stocks-to-watch-as-asco-conference-gets-underway-.html\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ABBV","symbol_name":"艾伯维公司","start_time":0,"source_url":"https://www.cnbc.com/2021/05/31/3-stocks-to-watch-as-asco-conference-gets-underway-.html","article_id":"1104481164","we_media_id":null,"thumbnails":[],"rights":{"source":"cnbc_highlight","url":"https://www.cnbc.com/2021/05/31/3-stocks-to-watch-as-asco-conference-gets-underway-.html","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.ArticleHeader-headline{#titleStyle#}a{#lv2TextColor#}.ArticleHeader-time, .Author-authorNameAndSocial a{#sourceStyle#;}","selectors":".PageBuilder-pageWrapper","filters":".ArticleHeader-eyebrow, .RelatedTags-relatedTags","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=1104481164","pubTimestamp":1622468928,"columns":[],"sourceInfo":{"source_id":"cnbc_highlight","name":"CNBC"},"weMediaInfo":null,"summary":"The annual ASCO meeting begins at the end of the week, a conference that has often provided a tailwi","collect":0,"end_time":0,"defaultTopTitle":"cnbc.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"ABBV":"艾伯维公司","GILD":"吉利德科学","MRK":"默沙东","REGN":"再生元制药公司","LLY":"礼来","HOOK":"Hookipa Pharma Inc"},"translate_title":"大型生物科技年会召开之际，三只股票值得关注","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ABBV":0.9,"GILD":0.9,"HOOK":0.9,"LLY":0.9,"MRK":0.9,"REGN":0.9},"content_text":"The annual ASCO meeting begins at the end of the week, a conference that has often provided a tailwind for biotech and pharma names.\nBiotech has been a laggard this year, gaining big in February and March but declining and trading in a choppy range since then.\nBank of America analyst Geoff Meacham identified three companies that could get a positive reception at the meeting.\nThe The American Society of Clinical Oncology meeting will be virtual for a second year, and runs from from June 4 to June 8. Meacham said it is important but ASCO may not provide the pop to stocks it did in other years.\n“ASCO was by far and away the biggest medical conference of the year, and people looked forward to that. And you would have company presentations in front of 30,000 oncologists,” he said. “There would be hundreds of Wall Streeters. You could get a very good handle on what was the buzz of the meeting. SInce it’s virtual, it doesn’t have as much of its charm.”\nBut Meacham said ASCO could still be positive. “You have data that’s brand new and that could lead to approvals and some very good products,” he said.\nMeacham said he’s still positive on biotech despite its lackluster performance. He especially likes mid-cap biotech.\n“We’ve been pretty positive on the group. Recognizing that drug pricing has been a little bit of a cloud over the past couple of years, and 2021 is no different,” said Meacham. “But when you look at the pipeline, the midcap biotech pipeline looks fantastic.”\nThe pipeline in big pharma is got but not as robust. “For the most part, it’s singles and doubles. But not surprisingly, midcap biotech has some home run potential but with more risk. That’s what drives the industry - the innovation and new therapies - and that’s why we’re still positive.”\n\nThe IBB iShares NASDAQ Biotech ETF gained 0.4% last week, but it is up just 0.3% year-to-date. The widely followed IBB was down 1.7% for the month of May.\nMeacham identified three companies that could get a positive reception at the ASCO meeting. Bank of America has a buy rating on all of them. One of those is big pharma Bristol-Myers Squibb.\n“Bristol is probably one of the winners,” he said. The company’s anti-LAG-3 antibody relatlimab melanoma treatment has been in development and there will be data from a large phase 3 trial. He said the product was used with its Opdivo, and could have a better safety profile than the current treatment of Opdivo combined with Yervoy. He does expect Opdivo and Yervoy to maintain the lead share of the market going forward.\nBig cap biotech Amgen is presenting on its lung cancer drug Lumakras, which received Food and Drug Administration approval Friday. The drug was approved to treat lung cancer patients with a genetic mutation known as KRAS. The approval came sooner than expected and sent Amgen shares up more than 1.1% Friday.\nHe said it could be combined with other therapy, like Opdivo. “That two drug combination could be really profound,” he said.\nBiotech company Seagen is going to present on its Padcev treatment for bladder and kidney cancer, launched last year. “This is an update of existing data,” he said. The data shows patients live longer.\nThe study is a small phase 2 trial, but there is another larger phase 3 trial that combines the therapy with Merck’s Keytruda.\nOther companies with data to be presented at ASCO include Eli Lilly,Merck,Regeneron,Hookipa,AbbVie, and Gilead.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[{"id":119397959,"gmtCreate":1622517886371,"gmtModify":1704185496918,"author":{"id":"3583019971396816","authorId":"3583019971396816","name":"Tigger777","avatar":"https://static.tigerbbs.com/53969c426622bc828bc9dda9aa263652","vip":1,"crmLevel":2,"crmLevelSwitch":0,"authorIdStr":"3583019971396816","idStr":"3583019971396816"},"htmlText":"Diversify the investment in&nbsp;BioNTech stocks&nbsp;","listText":"Diversify the investment in&nbsp;BioNTech stocks&nbsp;","text":"Diversify the investment in BioNTech stocks","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/119397959","repostId":1104481164,"repostType":4,"repost":{"id":"1104481164","kind":"news","pubTimestamp":1622468928,"share":"https://ttm.financial/m/news/1104481164?lang=&edition=fundamental","pubTime":"2021-05-31 21:48","market":"us","language":"en","title":"Three stocks to watch as a big annual biotech conference gets underway","url":"https://stock-news.laohu8.com/highlight/detail?id=1104481164","media":"CNBC","summary":"The annual ASCO meeting begins at the end of the week, a conference that has often provided a tailwi","content":"<div>\n<p>The annual ASCO meeting begins at the end of the week, a conference that has often provided a tailwind for biotech and pharma names.\nBiotech has been a laggard this year, gaining big in February and ...</p>\n\n<a href=\"https://www.cnbc.com/2021/05/31/3-stocks-to-watch-as-asco-conference-gets-underway-.html\">Web Link</a>\n\n</div>\n","source":"cnbc_highlight","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Three stocks to watch as a big annual biotech conference gets underway</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nThree stocks to watch as a big annual biotech conference gets underway\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-05-31 21:48 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.cnbc.com/2021/05/31/3-stocks-to-watch-as-asco-conference-gets-underway-.html><strong>CNBC</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The annual ASCO meeting begins at the end of the week, a conference that has often provided a tailwind for biotech and pharma names.\nBiotech has been a laggard this year, gaining big in February and ...</p>\n\n<a href=\"https://www.cnbc.com/2021/05/31/3-stocks-to-watch-as-asco-conference-gets-underway-.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"LLY":"礼来","ABBV":"艾伯维公司","REGN":"再生元制药公司","GILD":"吉利德科学","MRK":"默沙东","HOOK":"Hookipa Pharma Inc"},"source_url":"https://www.cnbc.com/2021/05/31/3-stocks-to-watch-as-asco-conference-gets-underway-.html","is_english":true,"share_image_url":"https://static.laohu8.com/72bb72e1b84c09fca865c6dcb1bbcd16","article_id":"1104481164","content_text":"The annual ASCO meeting begins at the end of the week, a conference that has often provided a tailwind for biotech and pharma names.\nBiotech has been a laggard this year, gaining big in February and March but declining and trading in a choppy range since then.\nBank of America analyst Geoff Meacham identified three companies that could get a positive reception at the meeting.\nThe The American Society of Clinical Oncology meeting will be virtual for a second year, and runs from from June 4 to June 8. Meacham said it is important but ASCO may not provide the pop to stocks it did in other years.\n“ASCO was by far and away the biggest medical conference of the year, and people looked forward to that. And you would have company presentations in front of 30,000 oncologists,” he said. “There would be hundreds of Wall Streeters. You could get a very good handle on what was the buzz of the meeting. SInce it’s virtual, it doesn’t have as much of its charm.”\nBut Meacham said ASCO could still be positive. “You have data that’s brand new and that could lead to approvals and some very good products,” he said.\nMeacham said he’s still positive on biotech despite its lackluster performance. He especially likes mid-cap biotech.\n“We’ve been pretty positive on the group. Recognizing that drug pricing has been a little bit of a cloud over the past couple of years, and 2021 is no different,” said Meacham. “But when you look at the pipeline, the midcap biotech pipeline looks fantastic.”\nThe pipeline in big pharma is got but not as robust. “For the most part, it’s singles and doubles. But not surprisingly, midcap biotech has some home run potential but with more risk. That’s what drives the industry - the innovation and new therapies - and that’s why we’re still positive.”\n\nThe IBB iShares NASDAQ Biotech ETF gained 0.4% last week, but it is up just 0.3% year-to-date. The widely followed IBB was down 1.7% for the month of May.\nMeacham identified three companies that could get a positive reception at the ASCO meeting. Bank of America has a buy rating on all of them. One of those is big pharma Bristol-Myers Squibb.\n“Bristol is probably one of the winners,” he said. The company’s anti-LAG-3 antibody relatlimab melanoma treatment has been in development and there will be data from a large phase 3 trial. He said the product was used with its Opdivo, and could have a better safety profile than the current treatment of Opdivo combined with Yervoy. He does expect Opdivo and Yervoy to maintain the lead share of the market going forward.\nBig cap biotech Amgen is presenting on its lung cancer drug Lumakras, which received Food and Drug Administration approval Friday. The drug was approved to treat lung cancer patients with a genetic mutation known as KRAS. The approval came sooner than expected and sent Amgen shares up more than 1.1% Friday.\nHe said it could be combined with other therapy, like Opdivo. “That two drug combination could be really profound,” he said.\nBiotech company Seagen is going to present on its Padcev treatment for bladder and kidney cancer, launched last year. “This is an update of existing data,” he said. The data shows patients live longer.\nThe study is a small phase 2 trial, but there is another larger phase 3 trial that combines the therapy with Merck’s Keytruda.\nOther companies with data to be presented at ASCO include Eli Lilly,Merck,Regeneron,Hookipa,AbbVie, and Gilead.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":110751875,"gmtCreate":1622505811497,"gmtModify":1704185163749,"author":{"id":"3578570760040163","authorId":"3578570760040163","name":"hmmwvms","avatar":"https://static.tigerbbs.com/a906b2444a1aca7cd161a6e1ee03687e","vip":1,"crmLevel":6,"crmLevelSwitch":0,"authorIdStr":"3578570760040163","idStr":"3578570760040163"},"htmlText":"L&amp;C (like and comment) please. Thank you :)&nbsp;","listText":"L&amp;C (like and comment) please. Thank you :)&nbsp;","text":"L&C (like and comment) please. Thank you :)","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":2,"repostSize":0,"link":"https://ttm.financial/post/110751875","repostId":1104481164,"repostType":4,"repost":{"id":"1104481164","kind":"news","pubTimestamp":1622468928,"share":"https://ttm.financial/m/news/1104481164?lang=&edition=fundamental","pubTime":"2021-05-31 21:48","market":"us","language":"en","title":"Three stocks to watch as a big annual biotech conference gets underway","url":"https://stock-news.laohu8.com/highlight/detail?id=1104481164","media":"CNBC","summary":"The annual ASCO meeting begins at the end of the week, a conference that has often provided a tailwi","content":"<div>\n<p>The annual ASCO meeting begins at the end of the week, a conference that has often provided a tailwind for biotech and pharma names.\nBiotech has been a laggard this year, gaining big in February and ...</p>\n\n<a href=\"https://www.cnbc.com/2021/05/31/3-stocks-to-watch-as-asco-conference-gets-underway-.html\">Web Link</a>\n\n</div>\n","source":"cnbc_highlight","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Three stocks to watch as a big annual biotech conference gets underway</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nThree stocks to watch as a big annual biotech conference gets underway\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-05-31 21:48 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.cnbc.com/2021/05/31/3-stocks-to-watch-as-asco-conference-gets-underway-.html><strong>CNBC</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The annual ASCO meeting begins at the end of the week, a conference that has often provided a tailwind for biotech and pharma names.\nBiotech has been a laggard this year, gaining big in February and ...</p>\n\n<a href=\"https://www.cnbc.com/2021/05/31/3-stocks-to-watch-as-asco-conference-gets-underway-.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"LLY":"礼来","ABBV":"艾伯维公司","REGN":"再生元制药公司","GILD":"吉利德科学","MRK":"默沙东","HOOK":"Hookipa Pharma Inc"},"source_url":"https://www.cnbc.com/2021/05/31/3-stocks-to-watch-as-asco-conference-gets-underway-.html","is_english":true,"share_image_url":"https://static.laohu8.com/72bb72e1b84c09fca865c6dcb1bbcd16","article_id":"1104481164","content_text":"The annual ASCO meeting begins at the end of the week, a conference that has often provided a tailwind for biotech and pharma names.\nBiotech has been a laggard this year, gaining big in February and March but declining and trading in a choppy range since then.\nBank of America analyst Geoff Meacham identified three companies that could get a positive reception at the meeting.\nThe The American Society of Clinical Oncology meeting will be virtual for a second year, and runs from from June 4 to June 8. Meacham said it is important but ASCO may not provide the pop to stocks it did in other years.\n“ASCO was by far and away the biggest medical conference of the year, and people looked forward to that. And you would have company presentations in front of 30,000 oncologists,” he said. “There would be hundreds of Wall Streeters. You could get a very good handle on what was the buzz of the meeting. SInce it’s virtual, it doesn’t have as much of its charm.”\nBut Meacham said ASCO could still be positive. “You have data that’s brand new and that could lead to approvals and some very good products,” he said.\nMeacham said he’s still positive on biotech despite its lackluster performance. He especially likes mid-cap biotech.\n“We’ve been pretty positive on the group. Recognizing that drug pricing has been a little bit of a cloud over the past couple of years, and 2021 is no different,” said Meacham. “But when you look at the pipeline, the midcap biotech pipeline looks fantastic.”\nThe pipeline in big pharma is got but not as robust. “For the most part, it’s singles and doubles. But not surprisingly, midcap biotech has some home run potential but with more risk. That’s what drives the industry - the innovation and new therapies - and that’s why we’re still positive.”\n\nThe IBB iShares NASDAQ Biotech ETF gained 0.4% last week, but it is up just 0.3% year-to-date. The widely followed IBB was down 1.7% for the month of May.\nMeacham identified three companies that could get a positive reception at the ASCO meeting. Bank of America has a buy rating on all of them. One of those is big pharma Bristol-Myers Squibb.\n“Bristol is probably one of the winners,” he said. The company’s anti-LAG-3 antibody relatlimab melanoma treatment has been in development and there will be data from a large phase 3 trial. He said the product was used with its Opdivo, and could have a better safety profile than the current treatment of Opdivo combined with Yervoy. He does expect Opdivo and Yervoy to maintain the lead share of the market going forward.\nBig cap biotech Amgen is presenting on its lung cancer drug Lumakras, which received Food and Drug Administration approval Friday. The drug was approved to treat lung cancer patients with a genetic mutation known as KRAS. The approval came sooner than expected and sent Amgen shares up more than 1.1% Friday.\nHe said it could be combined with other therapy, like Opdivo. “That two drug combination could be really profound,” he said.\nBiotech company Seagen is going to present on its Padcev treatment for bladder and kidney cancer, launched last year. “This is an update of existing data,” he said. The data shows patients live longer.\nThe study is a small phase 2 trial, but there is another larger phase 3 trial that combines the therapy with Merck’s Keytruda.\nOther companies with data to be presented at ASCO include Eli Lilly,Merck,Regeneron,Hookipa,AbbVie, and Gilead.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":4522662,"gmtCreate":1622507295120,"gmtModify":1680792268228,"authorId":3582015516749888,"author":{"id":3582015516749888,"idStr":"3582015516749888","authorId":3582015516749888,"name":"HH浩","avatar":"https://static.tigerbbs.com/2639351c97027c6f71c4d9729ef216d8","vip":1,"crmLevel":4,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":110751875,"type":1,"supId":0,"prevId":0,"content":"Reciprocate","text":"Reciprocate","html":"Reciprocate"},{"id":4522885,"gmtCreate":1622507867744,"gmtModify":1680792264788,"authorId":3578570760040163,"author":{"id":3578570760040163,"idStr":"3578570760040163","authorId":3578570760040163,"name":"hmmwvms","avatar":"https://static.tigerbbs.com/a906b2444a1aca7cd161a6e1ee03687e","vip":1,"crmLevel":6,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":110751875,"type":1,"supId":4522662,"prevId":0,"content":"Thank <u>you</u>","text":"Thank <u>you</u>","html":"Thank <u>you</u>"}],"langContent":"EN"},{"id":110762267,"gmtCreate":1622504977259,"gmtModify":1704185139753,"author":{"id":"3562498882012320","authorId":"3562498882012320","name":"Fartyclown","avatar":"https://static.tigerbbs.com/98da8c7130a89aa96f8dfc0e63f22fd3","vip":1,"crmLevel":2,"crmLevelSwitch":0,"authorIdStr":"3562498882012320","idStr":"3562498882012320"},"htmlText":"?","listText":"?","text":"?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":3,"repostSize":0,"link":"https://ttm.financial/post/110762267","repostId":1104481164,"repostType":4,"repost":{"id":"1104481164","kind":"news","pubTimestamp":1622468928,"share":"https://ttm.financial/m/news/1104481164?lang=&edition=fundamental","pubTime":"2021-05-31 21:48","market":"us","language":"en","title":"Three stocks to watch as a big annual biotech conference gets underway","url":"https://stock-news.laohu8.com/highlight/detail?id=1104481164","media":"CNBC","summary":"The annual ASCO meeting begins at the end of the week, a conference that has often provided a tailwi","content":"<div>\n<p>The annual ASCO meeting begins at the end of the week, a conference that has often provided a tailwind for biotech and pharma names.\nBiotech has been a laggard this year, gaining big in February and ...</p>\n\n<a href=\"https://www.cnbc.com/2021/05/31/3-stocks-to-watch-as-asco-conference-gets-underway-.html\">Web Link</a>\n\n</div>\n","source":"cnbc_highlight","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Three stocks to watch as a big annual biotech conference gets underway</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nThree stocks to watch as a big annual biotech conference gets underway\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-05-31 21:48 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.cnbc.com/2021/05/31/3-stocks-to-watch-as-asco-conference-gets-underway-.html><strong>CNBC</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The annual ASCO meeting begins at the end of the week, a conference that has often provided a tailwind for biotech and pharma names.\nBiotech has been a laggard this year, gaining big in February and ...</p>\n\n<a href=\"https://www.cnbc.com/2021/05/31/3-stocks-to-watch-as-asco-conference-gets-underway-.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"LLY":"礼来","ABBV":"艾伯维公司","REGN":"再生元制药公司","GILD":"吉利德科学","MRK":"默沙东","HOOK":"Hookipa Pharma Inc"},"source_url":"https://www.cnbc.com/2021/05/31/3-stocks-to-watch-as-asco-conference-gets-underway-.html","is_english":true,"share_image_url":"https://static.laohu8.com/72bb72e1b84c09fca865c6dcb1bbcd16","article_id":"1104481164","content_text":"The annual ASCO meeting begins at the end of the week, a conference that has often provided a tailwind for biotech and pharma names.\nBiotech has been a laggard this year, gaining big in February and March but declining and trading in a choppy range since then.\nBank of America analyst Geoff Meacham identified three companies that could get a positive reception at the meeting.\nThe The American Society of Clinical Oncology meeting will be virtual for a second year, and runs from from June 4 to June 8. Meacham said it is important but ASCO may not provide the pop to stocks it did in other years.\n“ASCO was by far and away the biggest medical conference of the year, and people looked forward to that. And you would have company presentations in front of 30,000 oncologists,” he said. “There would be hundreds of Wall Streeters. You could get a very good handle on what was the buzz of the meeting. SInce it’s virtual, it doesn’t have as much of its charm.”\nBut Meacham said ASCO could still be positive. “You have data that’s brand new and that could lead to approvals and some very good products,” he said.\nMeacham said he’s still positive on biotech despite its lackluster performance. He especially likes mid-cap biotech.\n“We’ve been pretty positive on the group. Recognizing that drug pricing has been a little bit of a cloud over the past couple of years, and 2021 is no different,” said Meacham. “But when you look at the pipeline, the midcap biotech pipeline looks fantastic.”\nThe pipeline in big pharma is got but not as robust. “For the most part, it’s singles and doubles. But not surprisingly, midcap biotech has some home run potential but with more risk. That’s what drives the industry - the innovation and new therapies - and that’s why we’re still positive.”\n\nThe IBB iShares NASDAQ Biotech ETF gained 0.4% last week, but it is up just 0.3% year-to-date. The widely followed IBB was down 1.7% for the month of May.\nMeacham identified three companies that could get a positive reception at the ASCO meeting. Bank of America has a buy rating on all of them. One of those is big pharma Bristol-Myers Squibb.\n“Bristol is probably one of the winners,” he said. The company’s anti-LAG-3 antibody relatlimab melanoma treatment has been in development and there will be data from a large phase 3 trial. He said the product was used with its Opdivo, and could have a better safety profile than the current treatment of Opdivo combined with Yervoy. He does expect Opdivo and Yervoy to maintain the lead share of the market going forward.\nBig cap biotech Amgen is presenting on its lung cancer drug Lumakras, which received Food and Drug Administration approval Friday. The drug was approved to treat lung cancer patients with a genetic mutation known as KRAS. The approval came sooner than expected and sent Amgen shares up more than 1.1% Friday.\nHe said it could be combined with other therapy, like Opdivo. “That two drug combination could be really profound,” he said.\nBiotech company Seagen is going to present on its Padcev treatment for bladder and kidney cancer, launched last year. “This is an update of existing data,” he said. The data shows patients live longer.\nThe study is a small phase 2 trial, but there is another larger phase 3 trial that combines the therapy with Merck’s Keytruda.\nOther companies with data to be presented at ASCO include Eli Lilly,Merck,Regeneron,Hookipa,AbbVie, and Gilead.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":4538685,"gmtCreate":1622596472663,"gmtModify":1680792543376,"authorId":3562498882012320,"author":{"id":3562498882012320,"idStr":"3562498882012320","authorId":3562498882012320,"name":"Fartyclown","avatar":"https://static.tigerbbs.com/98da8c7130a89aa96f8dfc0e63f22fd3","vip":1,"currentWearingBadge":{"badgeId":"972123088c9646f7b6091ae0662215be-2","templateUuid":"972123088c9646f7b6091ae0662215be","name":"Master Trader","description":"Total number of securities or futures transactions reached 100","bigImgUrl":"https://static.tigerbbs.com/ad22cfbe2d05aa393b18e9226e4b0307","smallImgUrl":"https://static.tigerbbs.com/36702e6ff3ffe46acafee66cc85273ca","grayImgUrl":"https://static.tigerbbs.com/d52eb88fa385cf5abe2616ed63781765","redirectLinkEnabled":0,"hasAllocated":1,"isWearing":1,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":"80.86%","individualDisplayEnabled":0,"individualDisplaySort":0,"categoryType":1100},"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":110762267,"type":1,"supId":0,"prevId":0,"content":".","text":".","html":"."},{"id":4530215,"gmtCreate":1622546629683,"gmtModify":1680792402473,"authorId":3562498882012320,"author":{"id":3562498882012320,"idStr":"3562498882012320","authorId":3562498882012320,"name":"Fartyclown","avatar":"https://static.tigerbbs.com/98da8c7130a89aa96f8dfc0e63f22fd3","vip":1,"currentWearingBadge":{"badgeId":"972123088c9646f7b6091ae0662215be-2","templateUuid":"972123088c9646f7b6091ae0662215be","name":"Master Trader","description":"Total number of securities or futures transactions reached 100","bigImgUrl":"https://static.tigerbbs.com/ad22cfbe2d05aa393b18e9226e4b0307","smallImgUrl":"https://static.tigerbbs.com/36702e6ff3ffe46acafee66cc85273ca","grayImgUrl":"https://static.tigerbbs.com/d52eb88fa385cf5abe2616ed63781765","redirectLinkEnabled":0,"hasAllocated":1,"isWearing":1,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":"80.86%","individualDisplayEnabled":0,"individualDisplaySort":0,"categoryType":1100},"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":110762267,"type":1,"supId":4529845,"prevId":0,"content":"??","text":"??","html":"??"},{"id":4529845,"gmtCreate":1622544263466,"gmtModify":1680792393222,"authorId":3566789787456860,"author":{"id":3566789787456860,"idStr":"3566789787456860","authorId":3566789787456860,"name":"Godskitchen","avatar":"https://static.tigerbbs.com/8e19dd36ba7c4a40f3b317fb4ef84d16","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":110762267,"type":1,"supId":0,"prevId":0,"content":"<u>skill</u>","text":"<u>skill</u>","html":"<u>skill</u>"}],"langContent":"EN"},{"id":110475003,"gmtCreate":1622501918902,"gmtModify":1704185059671,"author":{"id":"3578697890023823","authorId":"3578697890023823","name":"ryanlow","avatar":"https://static.tigerbbs.com/ef1ede5b3203c87007bdaeb19d8327f4","vip":1,"crmLevel":2,"crmLevelSwitch":0,"authorIdStr":"3578697890023823","idStr":"3578697890023823"},"htmlText":"wow","listText":"wow","text":"wow","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":2,"repostSize":0,"link":"https://ttm.financial/post/110475003","repostId":1104481164,"repostType":4,"repost":{"id":"1104481164","kind":"news","pubTimestamp":1622468928,"share":"https://ttm.financial/m/news/1104481164?lang=&edition=fundamental","pubTime":"2021-05-31 21:48","market":"us","language":"en","title":"Three stocks to watch as a big annual biotech conference gets underway","url":"https://stock-news.laohu8.com/highlight/detail?id=1104481164","media":"CNBC","summary":"The annual ASCO meeting begins at the end of the week, a conference that has often provided a tailwi","content":"<div>\n<p>The annual ASCO meeting begins at the end of the week, a conference that has often provided a tailwind for biotech and pharma names.\nBiotech has been a laggard this year, gaining big in February and ...</p>\n\n<a href=\"https://www.cnbc.com/2021/05/31/3-stocks-to-watch-as-asco-conference-gets-underway-.html\">Web Link</a>\n\n</div>\n","source":"cnbc_highlight","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Three stocks to watch as a big annual biotech conference gets underway</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nThree stocks to watch as a big annual biotech conference gets underway\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-05-31 21:48 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.cnbc.com/2021/05/31/3-stocks-to-watch-as-asco-conference-gets-underway-.html><strong>CNBC</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The annual ASCO meeting begins at the end of the week, a conference that has often provided a tailwind for biotech and pharma names.\nBiotech has been a laggard this year, gaining big in February and ...</p>\n\n<a href=\"https://www.cnbc.com/2021/05/31/3-stocks-to-watch-as-asco-conference-gets-underway-.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"LLY":"礼来","ABBV":"艾伯维公司","REGN":"再生元制药公司","GILD":"吉利德科学","MRK":"默沙东","HOOK":"Hookipa Pharma Inc"},"source_url":"https://www.cnbc.com/2021/05/31/3-stocks-to-watch-as-asco-conference-gets-underway-.html","is_english":true,"share_image_url":"https://static.laohu8.com/72bb72e1b84c09fca865c6dcb1bbcd16","article_id":"1104481164","content_text":"The annual ASCO meeting begins at the end of the week, a conference that has often provided a tailwind for biotech and pharma names.\nBiotech has been a laggard this year, gaining big in February and March but declining and trading in a choppy range since then.\nBank of America analyst Geoff Meacham identified three companies that could get a positive reception at the meeting.\nThe The American Society of Clinical Oncology meeting will be virtual for a second year, and runs from from June 4 to June 8. Meacham said it is important but ASCO may not provide the pop to stocks it did in other years.\n“ASCO was by far and away the biggest medical conference of the year, and people looked forward to that. And you would have company presentations in front of 30,000 oncologists,” he said. “There would be hundreds of Wall Streeters. You could get a very good handle on what was the buzz of the meeting. SInce it’s virtual, it doesn’t have as much of its charm.”\nBut Meacham said ASCO could still be positive. “You have data that’s brand new and that could lead to approvals and some very good products,” he said.\nMeacham said he’s still positive on biotech despite its lackluster performance. He especially likes mid-cap biotech.\n“We’ve been pretty positive on the group. Recognizing that drug pricing has been a little bit of a cloud over the past couple of years, and 2021 is no different,” said Meacham. “But when you look at the pipeline, the midcap biotech pipeline looks fantastic.”\nThe pipeline in big pharma is got but not as robust. “For the most part, it’s singles and doubles. But not surprisingly, midcap biotech has some home run potential but with more risk. That’s what drives the industry - the innovation and new therapies - and that’s why we’re still positive.”\n\nThe IBB iShares NASDAQ Biotech ETF gained 0.4% last week, but it is up just 0.3% year-to-date. The widely followed IBB was down 1.7% for the month of May.\nMeacham identified three companies that could get a positive reception at the ASCO meeting. Bank of America has a buy rating on all of them. One of those is big pharma Bristol-Myers Squibb.\n“Bristol is probably one of the winners,” he said. The company’s anti-LAG-3 antibody relatlimab melanoma treatment has been in development and there will be data from a large phase 3 trial. He said the product was used with its Opdivo, and could have a better safety profile than the current treatment of Opdivo combined with Yervoy. He does expect Opdivo and Yervoy to maintain the lead share of the market going forward.\nBig cap biotech Amgen is presenting on its lung cancer drug Lumakras, which received Food and Drug Administration approval Friday. The drug was approved to treat lung cancer patients with a genetic mutation known as KRAS. The approval came sooner than expected and sent Amgen shares up more than 1.1% Friday.\nHe said it could be combined with other therapy, like Opdivo. “That two drug combination could be really profound,” he said.\nBiotech company Seagen is going to present on its Padcev treatment for bladder and kidney cancer, launched last year. “This is an update of existing data,” he said. The data shows patients live longer.\nThe study is a small phase 2 trial, but there is another larger phase 3 trial that combines the therapy with Merck’s Keytruda.\nOther companies with data to be presented at ASCO include Eli Lilly,Merck,Regeneron,Hookipa,AbbVie, and Gilead.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":4521988,"gmtCreate":1622505005888,"gmtModify":1680792261453,"authorId":3576501151089163,"author":{"id":3576501151089163,"idStr":"3576501151089163","authorId":3576501151089163,"name":"aesemera","avatar":"https://static.tigerbbs.com/cdbbdd997dc9db0d9509166c15432fc2","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":110475003,"type":1,"supId":4521127,"prevId":0,"content":"cheers!","text":"cheers!","html":"cheers!"},{"id":4521127,"gmtCreate":1622502118286,"gmtModify":1680792236843,"authorId":3575958434174944,"author":{"id":3575958434174944,"idStr":"3575958434174944","authorId":3575958434174944,"name":"Shadotaiger","avatar":"https://static.tigerbbs.com/c26a9d060fabab1c1347edbfc7329574","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":110475003,"type":1,"supId":0,"prevId":0,"content":"reply?","text":"reply?","html":"reply?"}],"langContent":"EN"},{"id":110452421,"gmtCreate":1622500236463,"gmtModify":1704185032440,"author":{"id":"3581996355402655","authorId":"3581996355402655","name":"LiuQY","avatar":"https://static.tigerbbs.com/675aff70b593df96675c1c39cf1bbae0","vip":1,"crmLevel":2,"crmLevelSwitch":0,"authorIdStr":"3581996355402655","idStr":"3581996355402655"},"htmlText":"Gooooooooo","listText":"Gooooooooo","text":"Gooooooooo","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":2,"repostSize":0,"link":"https://ttm.financial/post/110452421","repostId":1104481164,"repostType":4,"repost":{"id":"1104481164","kind":"news","pubTimestamp":1622468928,"share":"https://ttm.financial/m/news/1104481164?lang=&edition=fundamental","pubTime":"2021-05-31 21:48","market":"us","language":"en","title":"Three stocks to watch as a big annual biotech conference gets underway","url":"https://stock-news.laohu8.com/highlight/detail?id=1104481164","media":"CNBC","summary":"The annual ASCO meeting begins at the end of the week, a conference that has often provided a tailwi","content":"<div>\n<p>The annual ASCO meeting begins at the end of the week, a conference that has often provided a tailwind for biotech and pharma names.\nBiotech has been a laggard this year, gaining big in February and ...</p>\n\n<a href=\"https://www.cnbc.com/2021/05/31/3-stocks-to-watch-as-asco-conference-gets-underway-.html\">Web Link</a>\n\n</div>\n","source":"cnbc_highlight","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Three stocks to watch as a big annual biotech conference gets underway</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nThree stocks to watch as a big annual biotech conference gets underway\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-05-31 21:48 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.cnbc.com/2021/05/31/3-stocks-to-watch-as-asco-conference-gets-underway-.html><strong>CNBC</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The annual ASCO meeting begins at the end of the week, a conference that has often provided a tailwind for biotech and pharma names.\nBiotech has been a laggard this year, gaining big in February and ...</p>\n\n<a href=\"https://www.cnbc.com/2021/05/31/3-stocks-to-watch-as-asco-conference-gets-underway-.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"LLY":"礼来","ABBV":"艾伯维公司","REGN":"再生元制药公司","GILD":"吉利德科学","MRK":"默沙东","HOOK":"Hookipa Pharma Inc"},"source_url":"https://www.cnbc.com/2021/05/31/3-stocks-to-watch-as-asco-conference-gets-underway-.html","is_english":true,"share_image_url":"https://static.laohu8.com/72bb72e1b84c09fca865c6dcb1bbcd16","article_id":"1104481164","content_text":"The annual ASCO meeting begins at the end of the week, a conference that has often provided a tailwind for biotech and pharma names.\nBiotech has been a laggard this year, gaining big in February and March but declining and trading in a choppy range since then.\nBank of America analyst Geoff Meacham identified three companies that could get a positive reception at the meeting.\nThe The American Society of Clinical Oncology meeting will be virtual for a second year, and runs from from June 4 to June 8. Meacham said it is important but ASCO may not provide the pop to stocks it did in other years.\n“ASCO was by far and away the biggest medical conference of the year, and people looked forward to that. And you would have company presentations in front of 30,000 oncologists,” he said. “There would be hundreds of Wall Streeters. You could get a very good handle on what was the buzz of the meeting. SInce it’s virtual, it doesn’t have as much of its charm.”\nBut Meacham said ASCO could still be positive. “You have data that’s brand new and that could lead to approvals and some very good products,” he said.\nMeacham said he’s still positive on biotech despite its lackluster performance. He especially likes mid-cap biotech.\n“We’ve been pretty positive on the group. Recognizing that drug pricing has been a little bit of a cloud over the past couple of years, and 2021 is no different,” said Meacham. “But when you look at the pipeline, the midcap biotech pipeline looks fantastic.”\nThe pipeline in big pharma is got but not as robust. “For the most part, it’s singles and doubles. But not surprisingly, midcap biotech has some home run potential but with more risk. That’s what drives the industry - the innovation and new therapies - and that’s why we’re still positive.”\n\nThe IBB iShares NASDAQ Biotech ETF gained 0.4% last week, but it is up just 0.3% year-to-date. The widely followed IBB was down 1.7% for the month of May.\nMeacham identified three companies that could get a positive reception at the ASCO meeting. Bank of America has a buy rating on all of them. One of those is big pharma Bristol-Myers Squibb.\n“Bristol is probably one of the winners,” he said. The company’s anti-LAG-3 antibody relatlimab melanoma treatment has been in development and there will be data from a large phase 3 trial. He said the product was used with its Opdivo, and could have a better safety profile than the current treatment of Opdivo combined with Yervoy. He does expect Opdivo and Yervoy to maintain the lead share of the market going forward.\nBig cap biotech Amgen is presenting on its lung cancer drug Lumakras, which received Food and Drug Administration approval Friday. The drug was approved to treat lung cancer patients with a genetic mutation known as KRAS. The approval came sooner than expected and sent Amgen shares up more than 1.1% Friday.\nHe said it could be combined with other therapy, like Opdivo. “That two drug combination could be really profound,” he said.\nBiotech company Seagen is going to present on its Padcev treatment for bladder and kidney cancer, launched last year. “This is an update of existing data,” he said. The data shows patients live longer.\nThe study is a small phase 2 trial, but there is another larger phase 3 trial that combines the therapy with Merck’s Keytruda.\nOther companies with data to be presented at ASCO include Eli Lilly,Merck,Regeneron,Hookipa,AbbVie, and Gilead.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":4521887,"gmtCreate":1622504678280,"gmtModify":1680792252411,"authorId":3575125836760247,"author":{"id":3575125836760247,"idStr":"3575125836760247","authorId":3575125836760247,"name":"Singman","avatar":"https://static.tigerbbs.com/d770feb757705f2d631d2d5f381ae07b","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":110452421,"type":1,"supId":0,"prevId":0,"content":"pls like and comment on me too.","text":"pls like and comment on me too.","html":"pls like and comment on me too."},{"id":4521092,"gmtCreate":1622501933579,"gmtModify":1680792238339,"authorId":3578697890023823,"author":{"id":3578697890023823,"idStr":"3578697890023823","authorId":3578697890023823,"name":"ryanlow","avatar":"https://static.tigerbbs.com/ef1ede5b3203c87007bdaeb19d8327f4","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":110452421,"type":1,"supId":0,"prevId":0,"content":"wow","text":"wow","html":"wow"}],"langContent":"EN"},{"id":110451824,"gmtCreate":1622499926068,"gmtModify":1704185027751,"author":{"id":"3571129545109571","authorId":"3571129545109571","name":"MrMrsBean","avatar":"https://static.tigerbbs.com/8f1ab99fec06884945521404915aec0e","vip":1,"crmLevel":2,"crmLevelSwitch":0,"authorIdStr":"3571129545109571","idStr":"3571129545109571"},"htmlText":"[強]&nbsp;","listText":"[強]&nbsp;","text":"[強]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/110451824","repostId":1104481164,"repostType":4,"repost":{"id":"1104481164","kind":"news","pubTimestamp":1622468928,"share":"https://ttm.financial/m/news/1104481164?lang=&edition=fundamental","pubTime":"2021-05-31 21:48","market":"us","language":"en","title":"Three stocks to watch as a big annual biotech conference gets underway","url":"https://stock-news.laohu8.com/highlight/detail?id=1104481164","media":"CNBC","summary":"The annual ASCO meeting begins at the end of the week, a conference that has often provided a tailwi","content":"<div>\n<p>The annual ASCO meeting begins at the end of the week, a conference that has often provided a tailwind for biotech and pharma names.\nBiotech has been a laggard this year, gaining big in February and ...</p>\n\n<a href=\"https://www.cnbc.com/2021/05/31/3-stocks-to-watch-as-asco-conference-gets-underway-.html\">Web Link</a>\n\n</div>\n","source":"cnbc_highlight","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Three stocks to watch as a big annual biotech conference gets underway</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nThree stocks to watch as a big annual biotech conference gets underway\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-05-31 21:48 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.cnbc.com/2021/05/31/3-stocks-to-watch-as-asco-conference-gets-underway-.html><strong>CNBC</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The annual ASCO meeting begins at the end of the week, a conference that has often provided a tailwind for biotech and pharma names.\nBiotech has been a laggard this year, gaining big in February and ...</p>\n\n<a href=\"https://www.cnbc.com/2021/05/31/3-stocks-to-watch-as-asco-conference-gets-underway-.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"LLY":"礼来","ABBV":"艾伯维公司","REGN":"再生元制药公司","GILD":"吉利德科学","MRK":"默沙东","HOOK":"Hookipa Pharma Inc"},"source_url":"https://www.cnbc.com/2021/05/31/3-stocks-to-watch-as-asco-conference-gets-underway-.html","is_english":true,"share_image_url":"https://static.laohu8.com/72bb72e1b84c09fca865c6dcb1bbcd16","article_id":"1104481164","content_text":"The annual ASCO meeting begins at the end of the week, a conference that has often provided a tailwind for biotech and pharma names.\nBiotech has been a laggard this year, gaining big in February and March but declining and trading in a choppy range since then.\nBank of America analyst Geoff Meacham identified three companies that could get a positive reception at the meeting.\nThe The American Society of Clinical Oncology meeting will be virtual for a second year, and runs from from June 4 to June 8. Meacham said it is important but ASCO may not provide the pop to stocks it did in other years.\n“ASCO was by far and away the biggest medical conference of the year, and people looked forward to that. And you would have company presentations in front of 30,000 oncologists,” he said. “There would be hundreds of Wall Streeters. You could get a very good handle on what was the buzz of the meeting. SInce it’s virtual, it doesn’t have as much of its charm.”\nBut Meacham said ASCO could still be positive. “You have data that’s brand new and that could lead to approvals and some very good products,” he said.\nMeacham said he’s still positive on biotech despite its lackluster performance. He especially likes mid-cap biotech.\n“We’ve been pretty positive on the group. Recognizing that drug pricing has been a little bit of a cloud over the past couple of years, and 2021 is no different,” said Meacham. “But when you look at the pipeline, the midcap biotech pipeline looks fantastic.”\nThe pipeline in big pharma is got but not as robust. “For the most part, it’s singles and doubles. But not surprisingly, midcap biotech has some home run potential but with more risk. That’s what drives the industry - the innovation and new therapies - and that’s why we’re still positive.”\n\nThe IBB iShares NASDAQ Biotech ETF gained 0.4% last week, but it is up just 0.3% year-to-date. The widely followed IBB was down 1.7% for the month of May.\nMeacham identified three companies that could get a positive reception at the ASCO meeting. Bank of America has a buy rating on all of them. One of those is big pharma Bristol-Myers Squibb.\n“Bristol is probably one of the winners,” he said. The company’s anti-LAG-3 antibody relatlimab melanoma treatment has been in development and there will be data from a large phase 3 trial. He said the product was used with its Opdivo, and could have a better safety profile than the current treatment of Opdivo combined with Yervoy. He does expect Opdivo and Yervoy to maintain the lead share of the market going forward.\nBig cap biotech Amgen is presenting on its lung cancer drug Lumakras, which received Food and Drug Administration approval Friday. The drug was approved to treat lung cancer patients with a genetic mutation known as KRAS. The approval came sooner than expected and sent Amgen shares up more than 1.1% Friday.\nHe said it could be combined with other therapy, like Opdivo. “That two drug combination could be really profound,” he said.\nBiotech company Seagen is going to present on its Padcev treatment for bladder and kidney cancer, launched last year. “This is an update of existing data,” he said. The data shows patients live longer.\nThe study is a small phase 2 trial, but there is another larger phase 3 trial that combines the therapy with Merck’s Keytruda.\nOther companies with data to be presented at ASCO include Eli Lilly,Merck,Regeneron,Hookipa,AbbVie, and Gilead.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":4521069,"gmtCreate":1622501826540,"gmtModify":1680792238056,"authorId":3582053708073909,"author":{"id":3582053708073909,"idStr":"3582053708073909","authorId":3582053708073909,"name":"WeiChyi","avatar":"https://static.tigerbbs.com/1215c6c4b4962560ae3ef6fe8d752a11","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":110451824,"type":1,"supId":0,"prevId":0,"content":"K","text":"K","html":"K"}],"langContent":"CN"},{"id":110453888,"gmtCreate":1622499758744,"gmtModify":1704185026136,"author":{"id":"3572213696829638","authorId":"3572213696829638","name":"Alannjy","avatar":"https://static.tigerbbs.com/ab326ac9056e88557b36f97dfdad9cac","vip":1,"crmLevel":4,"crmLevelSwitch":0,"authorIdStr":"3572213696829638","idStr":"3572213696829638"},"htmlText":"Like and comment","listText":"Like and comment","text":"Like and comment","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":2,"repostSize":0,"link":"https://ttm.financial/post/110453888","repostId":1104481164,"repostType":4,"repost":{"id":"1104481164","kind":"news","pubTimestamp":1622468928,"share":"https://ttm.financial/m/news/1104481164?lang=&edition=fundamental","pubTime":"2021-05-31 21:48","market":"us","language":"en","title":"Three stocks to watch as a big annual biotech conference gets underway","url":"https://stock-news.laohu8.com/highlight/detail?id=1104481164","media":"CNBC","summary":"The annual ASCO meeting begins at the end of the week, a conference that has often provided a tailwi","content":"<div>\n<p>The annual ASCO meeting begins at the end of the week, a conference that has often provided a tailwind for biotech and pharma names.\nBiotech has been a laggard this year, gaining big in February and ...</p>\n\n<a href=\"https://www.cnbc.com/2021/05/31/3-stocks-to-watch-as-asco-conference-gets-underway-.html\">Web Link</a>\n\n</div>\n","source":"cnbc_highlight","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Three stocks to watch as a big annual biotech conference gets underway</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nThree stocks to watch as a big annual biotech conference gets underway\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-05-31 21:48 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.cnbc.com/2021/05/31/3-stocks-to-watch-as-asco-conference-gets-underway-.html><strong>CNBC</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The annual ASCO meeting begins at the end of the week, a conference that has often provided a tailwind for biotech and pharma names.\nBiotech has been a laggard this year, gaining big in February and ...</p>\n\n<a href=\"https://www.cnbc.com/2021/05/31/3-stocks-to-watch-as-asco-conference-gets-underway-.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"LLY":"礼来","ABBV":"艾伯维公司","REGN":"再生元制药公司","GILD":"吉利德科学","MRK":"默沙东","HOOK":"Hookipa Pharma Inc"},"source_url":"https://www.cnbc.com/2021/05/31/3-stocks-to-watch-as-asco-conference-gets-underway-.html","is_english":true,"share_image_url":"https://static.laohu8.com/72bb72e1b84c09fca865c6dcb1bbcd16","article_id":"1104481164","content_text":"The annual ASCO meeting begins at the end of the week, a conference that has often provided a tailwind for biotech and pharma names.\nBiotech has been a laggard this year, gaining big in February and March but declining and trading in a choppy range since then.\nBank of America analyst Geoff Meacham identified three companies that could get a positive reception at the meeting.\nThe The American Society of Clinical Oncology meeting will be virtual for a second year, and runs from from June 4 to June 8. Meacham said it is important but ASCO may not provide the pop to stocks it did in other years.\n“ASCO was by far and away the biggest medical conference of the year, and people looked forward to that. And you would have company presentations in front of 30,000 oncologists,” he said. “There would be hundreds of Wall Streeters. You could get a very good handle on what was the buzz of the meeting. SInce it’s virtual, it doesn’t have as much of its charm.”\nBut Meacham said ASCO could still be positive. “You have data that’s brand new and that could lead to approvals and some very good products,” he said.\nMeacham said he’s still positive on biotech despite its lackluster performance. He especially likes mid-cap biotech.\n“We’ve been pretty positive on the group. Recognizing that drug pricing has been a little bit of a cloud over the past couple of years, and 2021 is no different,” said Meacham. “But when you look at the pipeline, the midcap biotech pipeline looks fantastic.”\nThe pipeline in big pharma is got but not as robust. “For the most part, it’s singles and doubles. But not surprisingly, midcap biotech has some home run potential but with more risk. That’s what drives the industry - the innovation and new therapies - and that’s why we’re still positive.”\n\nThe IBB iShares NASDAQ Biotech ETF gained 0.4% last week, but it is up just 0.3% year-to-date. The widely followed IBB was down 1.7% for the month of May.\nMeacham identified three companies that could get a positive reception at the ASCO meeting. Bank of America has a buy rating on all of them. One of those is big pharma Bristol-Myers Squibb.\n“Bristol is probably one of the winners,” he said. The company’s anti-LAG-3 antibody relatlimab melanoma treatment has been in development and there will be data from a large phase 3 trial. He said the product was used with its Opdivo, and could have a better safety profile than the current treatment of Opdivo combined with Yervoy. He does expect Opdivo and Yervoy to maintain the lead share of the market going forward.\nBig cap biotech Amgen is presenting on its lung cancer drug Lumakras, which received Food and Drug Administration approval Friday. The drug was approved to treat lung cancer patients with a genetic mutation known as KRAS. The approval came sooner than expected and sent Amgen shares up more than 1.1% Friday.\nHe said it could be combined with other therapy, like Opdivo. “That two drug combination could be really profound,” he said.\nBiotech company Seagen is going to present on its Padcev treatment for bladder and kidney cancer, launched last year. “This is an update of existing data,” he said. The data shows patients live longer.\nThe study is a small phase 2 trial, but there is another larger phase 3 trial that combines the therapy with Merck’s Keytruda.\nOther companies with data to be presented at ASCO include Eli Lilly,Merck,Regeneron,Hookipa,AbbVie, and Gilead.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":4525398,"gmtCreate":1622516796792,"gmtModify":1680792311254,"authorId":3581631227222192,"author":{"id":3581631227222192,"idStr":"3581631227222192","authorId":3581631227222192,"name":"Mythology","avatar":"https://static.tigerbbs.com/190cafdd30075e07fb377edd392ed682","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":110453888,"type":1,"supId":0,"prevId":0,"content":"?","text":"?","html":"?"},{"id":4521050,"gmtCreate":1622501755008,"gmtModify":1680792243594,"authorId":3576697370297478,"author":{"id":3576697370297478,"idStr":"3576697370297478","authorId":3576697370297478,"name":"CLONGER","avatar":"https://static.itradeup.com/news/7239f28aff6577c21c21738bac5cb6eb","vip":1,"crmLevel":4,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":110453888,"type":1,"supId":0,"prevId":0,"content":"Done.","text":"Done.","html":"Done."}],"langContent":"EN"},{"id":110450162,"gmtCreate":1622499318256,"gmtModify":1704185023397,"author":{"id":"3569807126010989","authorId":"3569807126010989","name":"happymoney","avatar":"https://static.tigerbbs.com/c7b835f693b89bd9b980cc013a40c669","vip":1,"crmLevel":7,"crmLevelSwitch":1,"authorIdStr":"3569807126010989","idStr":"3569807126010989"},"htmlText":"Bio","listText":"Bio","text":"Bio","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":2,"repostSize":0,"link":"https://ttm.financial/post/110450162","repostId":1104481164,"repostType":4,"repost":{"id":"1104481164","kind":"news","pubTimestamp":1622468928,"share":"https://ttm.financial/m/news/1104481164?lang=&edition=fundamental","pubTime":"2021-05-31 21:48","market":"us","language":"en","title":"Three stocks to watch as a big annual biotech conference gets underway","url":"https://stock-news.laohu8.com/highlight/detail?id=1104481164","media":"CNBC","summary":"The annual ASCO meeting begins at the end of the week, a conference that has often provided a tailwi","content":"<div>\n<p>The annual ASCO meeting begins at the end of the week, a conference that has often provided a tailwind for biotech and pharma names.\nBiotech has been a laggard this year, gaining big in February and ...</p>\n\n<a href=\"https://www.cnbc.com/2021/05/31/3-stocks-to-watch-as-asco-conference-gets-underway-.html\">Web Link</a>\n\n</div>\n","source":"cnbc_highlight","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Three stocks to watch as a big annual biotech conference gets underway</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nThree stocks to watch as a big annual biotech conference gets underway\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-05-31 21:48 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.cnbc.com/2021/05/31/3-stocks-to-watch-as-asco-conference-gets-underway-.html><strong>CNBC</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The annual ASCO meeting begins at the end of the week, a conference that has often provided a tailwind for biotech and pharma names.\nBiotech has been a laggard this year, gaining big in February and ...</p>\n\n<a href=\"https://www.cnbc.com/2021/05/31/3-stocks-to-watch-as-asco-conference-gets-underway-.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"LLY":"礼来","ABBV":"艾伯维公司","REGN":"再生元制药公司","GILD":"吉利德科学","MRK":"默沙东","HOOK":"Hookipa Pharma Inc"},"source_url":"https://www.cnbc.com/2021/05/31/3-stocks-to-watch-as-asco-conference-gets-underway-.html","is_english":true,"share_image_url":"https://static.laohu8.com/72bb72e1b84c09fca865c6dcb1bbcd16","article_id":"1104481164","content_text":"The annual ASCO meeting begins at the end of the week, a conference that has often provided a tailwind for biotech and pharma names.\nBiotech has been a laggard this year, gaining big in February and March but declining and trading in a choppy range since then.\nBank of America analyst Geoff Meacham identified three companies that could get a positive reception at the meeting.\nThe The American Society of Clinical Oncology meeting will be virtual for a second year, and runs from from June 4 to June 8. Meacham said it is important but ASCO may not provide the pop to stocks it did in other years.\n“ASCO was by far and away the biggest medical conference of the year, and people looked forward to that. And you would have company presentations in front of 30,000 oncologists,” he said. “There would be hundreds of Wall Streeters. You could get a very good handle on what was the buzz of the meeting. SInce it’s virtual, it doesn’t have as much of its charm.”\nBut Meacham said ASCO could still be positive. “You have data that’s brand new and that could lead to approvals and some very good products,” he said.\nMeacham said he’s still positive on biotech despite its lackluster performance. He especially likes mid-cap biotech.\n“We’ve been pretty positive on the group. Recognizing that drug pricing has been a little bit of a cloud over the past couple of years, and 2021 is no different,” said Meacham. “But when you look at the pipeline, the midcap biotech pipeline looks fantastic.”\nThe pipeline in big pharma is got but not as robust. “For the most part, it’s singles and doubles. But not surprisingly, midcap biotech has some home run potential but with more risk. That’s what drives the industry - the innovation and new therapies - and that’s why we’re still positive.”\n\nThe IBB iShares NASDAQ Biotech ETF gained 0.4% last week, but it is up just 0.3% year-to-date. The widely followed IBB was down 1.7% for the month of May.\nMeacham identified three companies that could get a positive reception at the ASCO meeting. Bank of America has a buy rating on all of them. One of those is big pharma Bristol-Myers Squibb.\n“Bristol is probably one of the winners,” he said. The company’s anti-LAG-3 antibody relatlimab melanoma treatment has been in development and there will be data from a large phase 3 trial. He said the product was used with its Opdivo, and could have a better safety profile than the current treatment of Opdivo combined with Yervoy. He does expect Opdivo and Yervoy to maintain the lead share of the market going forward.\nBig cap biotech Amgen is presenting on its lung cancer drug Lumakras, which received Food and Drug Administration approval Friday. The drug was approved to treat lung cancer patients with a genetic mutation known as KRAS. The approval came sooner than expected and sent Amgen shares up more than 1.1% Friday.\nHe said it could be combined with other therapy, like Opdivo. “That two drug combination could be really profound,” he said.\nBiotech company Seagen is going to present on its Padcev treatment for bladder and kidney cancer, launched last year. “This is an update of existing data,” he said. The data shows patients live longer.\nThe study is a small phase 2 trial, but there is another larger phase 3 trial that combines the therapy with Merck’s Keytruda.\nOther companies with data to be presented at ASCO include Eli Lilly,Merck,Regeneron,Hookipa,AbbVie, and Gilead.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":4529293,"gmtCreate":1622540343832,"gmtModify":1680792386547,"authorId":3569807126010989,"author":{"id":3569807126010989,"idStr":"3569807126010989","authorId":3569807126010989,"name":"happymoney","avatar":"https://static.tigerbbs.com/c7b835f693b89bd9b980cc013a40c669","vip":1,"crmLevel":7,"crmLevelSwitch":1,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":110450162,"type":1,"supId":4520609,"prevId":0,"content":"Likey","text":"Likey","html":"Likey"},{"id":4520609,"gmtCreate":1622499772418,"gmtModify":1680792231294,"authorId":3572213696829638,"author":{"id":3572213696829638,"idStr":"3572213696829638","authorId":3572213696829638,"name":"Alannjy","avatar":"https://static.tigerbbs.com/ab326ac9056e88557b36f97dfdad9cac","vip":1,"crmLevel":4,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":110450162,"type":1,"supId":0,"prevId":0,"content":"Like and comment","text":"Like and comment","html":"Like and comment"}],"langContent":"EN"},{"id":110422652,"gmtCreate":1622498836676,"gmtModify":1704185018075,"author":{"id":"3574496739465198","authorId":"3574496739465198","name":"Genes","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":1,"crmLevelSwitch":0,"authorIdStr":"3574496739465198","idStr":"3574496739465198"},"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":2,"repostSize":0,"link":"https://ttm.financial/post/110422652","repostId":1104481164,"repostType":4,"repost":{"id":"1104481164","kind":"news","pubTimestamp":1622468928,"share":"https://ttm.financial/m/news/1104481164?lang=&edition=fundamental","pubTime":"2021-05-31 21:48","market":"us","language":"en","title":"Three stocks to watch as a big annual biotech conference gets underway","url":"https://stock-news.laohu8.com/highlight/detail?id=1104481164","media":"CNBC","summary":"The annual ASCO meeting begins at the end of the week, a conference that has often provided a tailwi","content":"<div>\n<p>The annual ASCO meeting begins at the end of the week, a conference that has often provided a tailwind for biotech and pharma names.\nBiotech has been a laggard this year, gaining big in February and ...</p>\n\n<a href=\"https://www.cnbc.com/2021/05/31/3-stocks-to-watch-as-asco-conference-gets-underway-.html\">Web Link</a>\n\n</div>\n","source":"cnbc_highlight","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Three stocks to watch as a big annual biotech conference gets underway</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nThree stocks to watch as a big annual biotech conference gets underway\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-05-31 21:48 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.cnbc.com/2021/05/31/3-stocks-to-watch-as-asco-conference-gets-underway-.html><strong>CNBC</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The annual ASCO meeting begins at the end of the week, a conference that has often provided a tailwind for biotech and pharma names.\nBiotech has been a laggard this year, gaining big in February and ...</p>\n\n<a href=\"https://www.cnbc.com/2021/05/31/3-stocks-to-watch-as-asco-conference-gets-underway-.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"LLY":"礼来","ABBV":"艾伯维公司","REGN":"再生元制药公司","GILD":"吉利德科学","MRK":"默沙东","HOOK":"Hookipa Pharma Inc"},"source_url":"https://www.cnbc.com/2021/05/31/3-stocks-to-watch-as-asco-conference-gets-underway-.html","is_english":true,"share_image_url":"https://static.laohu8.com/72bb72e1b84c09fca865c6dcb1bbcd16","article_id":"1104481164","content_text":"The annual ASCO meeting begins at the end of the week, a conference that has often provided a tailwind for biotech and pharma names.\nBiotech has been a laggard this year, gaining big in February and March but declining and trading in a choppy range since then.\nBank of America analyst Geoff Meacham identified three companies that could get a positive reception at the meeting.\nThe The American Society of Clinical Oncology meeting will be virtual for a second year, and runs from from June 4 to June 8. Meacham said it is important but ASCO may not provide the pop to stocks it did in other years.\n“ASCO was by far and away the biggest medical conference of the year, and people looked forward to that. And you would have company presentations in front of 30,000 oncologists,” he said. “There would be hundreds of Wall Streeters. You could get a very good handle on what was the buzz of the meeting. SInce it’s virtual, it doesn’t have as much of its charm.”\nBut Meacham said ASCO could still be positive. “You have data that’s brand new and that could lead to approvals and some very good products,” he said.\nMeacham said he’s still positive on biotech despite its lackluster performance. He especially likes mid-cap biotech.\n“We’ve been pretty positive on the group. Recognizing that drug pricing has been a little bit of a cloud over the past couple of years, and 2021 is no different,” said Meacham. “But when you look at the pipeline, the midcap biotech pipeline looks fantastic.”\nThe pipeline in big pharma is got but not as robust. “For the most part, it’s singles and doubles. But not surprisingly, midcap biotech has some home run potential but with more risk. That’s what drives the industry - the innovation and new therapies - and that’s why we’re still positive.”\n\nThe IBB iShares NASDAQ Biotech ETF gained 0.4% last week, but it is up just 0.3% year-to-date. The widely followed IBB was down 1.7% for the month of May.\nMeacham identified three companies that could get a positive reception at the ASCO meeting. Bank of America has a buy rating on all of them. One of those is big pharma Bristol-Myers Squibb.\n“Bristol is probably one of the winners,” he said. The company’s anti-LAG-3 antibody relatlimab melanoma treatment has been in development and there will be data from a large phase 3 trial. He said the product was used with its Opdivo, and could have a better safety profile than the current treatment of Opdivo combined with Yervoy. He does expect Opdivo and Yervoy to maintain the lead share of the market going forward.\nBig cap biotech Amgen is presenting on its lung cancer drug Lumakras, which received Food and Drug Administration approval Friday. The drug was approved to treat lung cancer patients with a genetic mutation known as KRAS. The approval came sooner than expected and sent Amgen shares up more than 1.1% Friday.\nHe said it could be combined with other therapy, like Opdivo. “That two drug combination could be really profound,” he said.\nBiotech company Seagen is going to present on its Padcev treatment for bladder and kidney cancer, launched last year. “This is an update of existing data,” he said. The data shows patients live longer.\nThe study is a small phase 2 trial, but there is another larger phase 3 trial that combines the therapy with Merck’s Keytruda.\nOther companies with data to be presented at ASCO include Eli Lilly,Merck,Regeneron,Hookipa,AbbVie, and Gilead.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":4520611,"gmtCreate":1622499780599,"gmtModify":1680792230180,"authorId":3572213696829638,"author":{"id":3572213696829638,"idStr":"3572213696829638","authorId":3572213696829638,"name":"Alannjy","avatar":"https://static.tigerbbs.com/ab326ac9056e88557b36f97dfdad9cac","vip":1,"crmLevel":4,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":110422652,"type":1,"supId":4520561,"prevId":0,"content":"Like and comment","text":"Like and comment","html":"Like and comment"},{"id":4520561,"gmtCreate":1622499063536,"gmtModify":1680792227745,"authorId":3579812664530236,"author":{"id":3579812664530236,"idStr":"3579812664530236","authorId":3579812664530236,"name":"RAMA","avatar":"https://static.tigerbbs.com/767f54a66ea074248d8e9bba9e219fce","vip":1,"crmLevel":5,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":110422652,"type":1,"supId":0,"prevId":0,"content":"LookS Good","text":"LookS Good","html":"LookS Good"}],"langContent":"EN"},{"id":110466166,"gmtCreate":1622496782855,"gmtModify":1704185003833,"author":{"id":"3582063342503280","authorId":"3582063342503280","name":"banchin","avatar":"https://static.tigerbbs.com/5c4c72eded6f6ba8a8c66bbf3cd0e90c","vip":1,"hat":"https://static.tigerbbs.com/7b75ce0c34afff716602792a5d0929dd","crmLevel":5,"crmLevelSwitch":0,"authorIdStr":"3582063342503280","idStr":"3582063342503280"},"htmlText":"Please give me comments and like&nbsp;","listText":"Please give me comments and like&nbsp;","text":"Please give me comments and like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":2,"repostSize":0,"link":"https://ttm.financial/post/110466166","repostId":1104481164,"repostType":4,"repost":{"id":"1104481164","kind":"news","pubTimestamp":1622468928,"share":"https://ttm.financial/m/news/1104481164?lang=&edition=fundamental","pubTime":"2021-05-31 21:48","market":"us","language":"en","title":"Three stocks to watch as a big annual biotech conference gets underway","url":"https://stock-news.laohu8.com/highlight/detail?id=1104481164","media":"CNBC","summary":"The annual ASCO meeting begins at the end of the week, a conference that has often provided a tailwi","content":"<div>\n<p>The annual ASCO meeting begins at the end of the week, a conference that has often provided a tailwind for biotech and pharma names.\nBiotech has been a laggard this year, gaining big in February and ...</p>\n\n<a href=\"https://www.cnbc.com/2021/05/31/3-stocks-to-watch-as-asco-conference-gets-underway-.html\">Web Link</a>\n\n</div>\n","source":"cnbc_highlight","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Three stocks to watch as a big annual biotech conference gets underway</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nThree stocks to watch as a big annual biotech conference gets underway\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-05-31 21:48 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.cnbc.com/2021/05/31/3-stocks-to-watch-as-asco-conference-gets-underway-.html><strong>CNBC</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The annual ASCO meeting begins at the end of the week, a conference that has often provided a tailwind for biotech and pharma names.\nBiotech has been a laggard this year, gaining big in February and ...</p>\n\n<a href=\"https://www.cnbc.com/2021/05/31/3-stocks-to-watch-as-asco-conference-gets-underway-.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"LLY":"礼来","ABBV":"艾伯维公司","REGN":"再生元制药公司","GILD":"吉利德科学","MRK":"默沙东","HOOK":"Hookipa Pharma Inc"},"source_url":"https://www.cnbc.com/2021/05/31/3-stocks-to-watch-as-asco-conference-gets-underway-.html","is_english":true,"share_image_url":"https://static.laohu8.com/72bb72e1b84c09fca865c6dcb1bbcd16","article_id":"1104481164","content_text":"The annual ASCO meeting begins at the end of the week, a conference that has often provided a tailwind for biotech and pharma names.\nBiotech has been a laggard this year, gaining big in February and March but declining and trading in a choppy range since then.\nBank of America analyst Geoff Meacham identified three companies that could get a positive reception at the meeting.\nThe The American Society of Clinical Oncology meeting will be virtual for a second year, and runs from from June 4 to June 8. Meacham said it is important but ASCO may not provide the pop to stocks it did in other years.\n“ASCO was by far and away the biggest medical conference of the year, and people looked forward to that. And you would have company presentations in front of 30,000 oncologists,” he said. “There would be hundreds of Wall Streeters. You could get a very good handle on what was the buzz of the meeting. SInce it’s virtual, it doesn’t have as much of its charm.”\nBut Meacham said ASCO could still be positive. “You have data that’s brand new and that could lead to approvals and some very good products,” he said.\nMeacham said he’s still positive on biotech despite its lackluster performance. He especially likes mid-cap biotech.\n“We’ve been pretty positive on the group. Recognizing that drug pricing has been a little bit of a cloud over the past couple of years, and 2021 is no different,” said Meacham. “But when you look at the pipeline, the midcap biotech pipeline looks fantastic.”\nThe pipeline in big pharma is got but not as robust. “For the most part, it’s singles and doubles. But not surprisingly, midcap biotech has some home run potential but with more risk. That’s what drives the industry - the innovation and new therapies - and that’s why we’re still positive.”\n\nThe IBB iShares NASDAQ Biotech ETF gained 0.4% last week, but it is up just 0.3% year-to-date. The widely followed IBB was down 1.7% for the month of May.\nMeacham identified three companies that could get a positive reception at the ASCO meeting. Bank of America has a buy rating on all of them. One of those is big pharma Bristol-Myers Squibb.\n“Bristol is probably one of the winners,” he said. The company’s anti-LAG-3 antibody relatlimab melanoma treatment has been in development and there will be data from a large phase 3 trial. He said the product was used with its Opdivo, and could have a better safety profile than the current treatment of Opdivo combined with Yervoy. He does expect Opdivo and Yervoy to maintain the lead share of the market going forward.\nBig cap biotech Amgen is presenting on its lung cancer drug Lumakras, which received Food and Drug Administration approval Friday. The drug was approved to treat lung cancer patients with a genetic mutation known as KRAS. The approval came sooner than expected and sent Amgen shares up more than 1.1% Friday.\nHe said it could be combined with other therapy, like Opdivo. “That two drug combination could be really profound,” he said.\nBiotech company Seagen is going to present on its Padcev treatment for bladder and kidney cancer, launched last year. “This is an update of existing data,” he said. The data shows patients live longer.\nThe study is a small phase 2 trial, but there is another larger phase 3 trial that combines the therapy with Merck’s Keytruda.\nOther companies with data to be presented at ASCO include Eli Lilly,Merck,Regeneron,Hookipa,AbbVie, and Gilead.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":4520613,"gmtCreate":1622499789789,"gmtModify":1680792234100,"authorId":3572213696829638,"author":{"id":3572213696829638,"idStr":"3572213696829638","authorId":3572213696829638,"name":"Alannjy","avatar":"https://static.tigerbbs.com/ab326ac9056e88557b36f97dfdad9cac","vip":1,"crmLevel":4,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":110466166,"type":1,"supId":4520553,"prevId":0,"content":"Like and comment","text":"Like and comment","html":"Like and comment"},{"id":4520553,"gmtCreate":1622498912002,"gmtModify":1680792227317,"authorId":3577917241557928,"author":{"id":3577917241557928,"idStr":"3577917241557928","authorId":3577917241557928,"name":"Andtendo","avatar":"https://static.tigerbbs.com/a36b92c865704901397ab4e190d5ad8a","vip":1,"crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":110466166,"type":1,"supId":0,"prevId":0,"content":"Ok","text":"Ok","html":"Ok"}],"langContent":"EN"},{"id":110480373,"gmtCreate":1622482973192,"gmtModify":1704184984255,"author":{"id":"3581903272361795","authorId":"3581903272361795","name":"WWX2020","avatar":"https://static.tigerbbs.com/245714e5ed56129262fa83e84d303ea3","vip":1,"crmLevel":2,"crmLevelSwitch":0,"authorIdStr":"3581903272361795","idStr":"3581903272361795"},"htmlText":"This is odd","listText":"This is odd","text":"This is odd","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/110480373","repostId":1104481164,"repostType":4,"repost":{"id":"1104481164","kind":"news","pubTimestamp":1622468928,"share":"https://ttm.financial/m/news/1104481164?lang=&edition=fundamental","pubTime":"2021-05-31 21:48","market":"us","language":"en","title":"Three stocks to watch as a big annual biotech conference gets underway","url":"https://stock-news.laohu8.com/highlight/detail?id=1104481164","media":"CNBC","summary":"The annual ASCO meeting begins at the end of the week, a conference that has often provided a tailwi","content":"<div>\n<p>The annual ASCO meeting begins at the end of the week, a conference that has often provided a tailwind for biotech and pharma names.\nBiotech has been a laggard this year, gaining big in February and ...</p>\n\n<a href=\"https://www.cnbc.com/2021/05/31/3-stocks-to-watch-as-asco-conference-gets-underway-.html\">Web Link</a>\n\n</div>\n","source":"cnbc_highlight","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Three stocks to watch as a big annual biotech conference gets underway</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nThree stocks to watch as a big annual biotech conference gets underway\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-05-31 21:48 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.cnbc.com/2021/05/31/3-stocks-to-watch-as-asco-conference-gets-underway-.html><strong>CNBC</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The annual ASCO meeting begins at the end of the week, a conference that has often provided a tailwind for biotech and pharma names.\nBiotech has been a laggard this year, gaining big in February and ...</p>\n\n<a href=\"https://www.cnbc.com/2021/05/31/3-stocks-to-watch-as-asco-conference-gets-underway-.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"LLY":"礼来","ABBV":"艾伯维公司","REGN":"再生元制药公司","GILD":"吉利德科学","MRK":"默沙东","HOOK":"Hookipa Pharma Inc"},"source_url":"https://www.cnbc.com/2021/05/31/3-stocks-to-watch-as-asco-conference-gets-underway-.html","is_english":true,"share_image_url":"https://static.laohu8.com/72bb72e1b84c09fca865c6dcb1bbcd16","article_id":"1104481164","content_text":"The annual ASCO meeting begins at the end of the week, a conference that has often provided a tailwind for biotech and pharma names.\nBiotech has been a laggard this year, gaining big in February and March but declining and trading in a choppy range since then.\nBank of America analyst Geoff Meacham identified three companies that could get a positive reception at the meeting.\nThe The American Society of Clinical Oncology meeting will be virtual for a second year, and runs from from June 4 to June 8. Meacham said it is important but ASCO may not provide the pop to stocks it did in other years.\n“ASCO was by far and away the biggest medical conference of the year, and people looked forward to that. And you would have company presentations in front of 30,000 oncologists,” he said. “There would be hundreds of Wall Streeters. You could get a very good handle on what was the buzz of the meeting. SInce it’s virtual, it doesn’t have as much of its charm.”\nBut Meacham said ASCO could still be positive. “You have data that’s brand new and that could lead to approvals and some very good products,” he said.\nMeacham said he’s still positive on biotech despite its lackluster performance. He especially likes mid-cap biotech.\n“We’ve been pretty positive on the group. Recognizing that drug pricing has been a little bit of a cloud over the past couple of years, and 2021 is no different,” said Meacham. “But when you look at the pipeline, the midcap biotech pipeline looks fantastic.”\nThe pipeline in big pharma is got but not as robust. “For the most part, it’s singles and doubles. But not surprisingly, midcap biotech has some home run potential but with more risk. That’s what drives the industry - the innovation and new therapies - and that’s why we’re still positive.”\n\nThe IBB iShares NASDAQ Biotech ETF gained 0.4% last week, but it is up just 0.3% year-to-date. The widely followed IBB was down 1.7% for the month of May.\nMeacham identified three companies that could get a positive reception at the ASCO meeting. Bank of America has a buy rating on all of them. One of those is big pharma Bristol-Myers Squibb.\n“Bristol is probably one of the winners,” he said. The company’s anti-LAG-3 antibody relatlimab melanoma treatment has been in development and there will be data from a large phase 3 trial. He said the product was used with its Opdivo, and could have a better safety profile than the current treatment of Opdivo combined with Yervoy. He does expect Opdivo and Yervoy to maintain the lead share of the market going forward.\nBig cap biotech Amgen is presenting on its lung cancer drug Lumakras, which received Food and Drug Administration approval Friday. The drug was approved to treat lung cancer patients with a genetic mutation known as KRAS. The approval came sooner than expected and sent Amgen shares up more than 1.1% Friday.\nHe said it could be combined with other therapy, like Opdivo. “That two drug combination could be really profound,” he said.\nBiotech company Seagen is going to present on its Padcev treatment for bladder and kidney cancer, launched last year. “This is an update of existing data,” he said. The data shows patients live longer.\nThe study is a small phase 2 trial, but there is another larger phase 3 trial that combines the therapy with Merck’s Keytruda.\nOther companies with data to be presented at ASCO include Eli Lilly,Merck,Regeneron,Hookipa,AbbVie, and Gilead.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":4520679,"gmtCreate":1622500259561,"gmtModify":1680792230936,"authorId":3581996355402655,"author":{"id":3581996355402655,"idStr":"3581996355402655","authorId":3581996355402655,"name":"LiuQY","avatar":"https://static.tigerbbs.com/675aff70b593df96675c1c39cf1bbae0","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":110480373,"type":1,"supId":0,"prevId":0,"content":"Hiiiii","text":"Hiiiii","html":"Hiiiii"}],"langContent":"EN"},{"id":110480983,"gmtCreate":1622482861942,"gmtModify":1704184984095,"author":{"id":"3581903272361795","authorId":"3581903272361795","name":"WWX2020","avatar":"https://static.tigerbbs.com/245714e5ed56129262fa83e84d303ea3","vip":1,"crmLevel":2,"crmLevelSwitch":0,"authorIdStr":"3581903272361795","idStr":"3581903272361795"},"htmlText":"Please like","listText":"Please like","text":"Please like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/110480983","repostId":1104481164,"repostType":4,"repost":{"id":"1104481164","kind":"news","pubTimestamp":1622468928,"share":"https://ttm.financial/m/news/1104481164?lang=&edition=fundamental","pubTime":"2021-05-31 21:48","market":"us","language":"en","title":"Three stocks to watch as a big annual biotech conference gets underway","url":"https://stock-news.laohu8.com/highlight/detail?id=1104481164","media":"CNBC","summary":"The annual ASCO meeting begins at the end of the week, a conference that has often provided a tailwi","content":"<div>\n<p>The annual ASCO meeting begins at the end of the week, a conference that has often provided a tailwind for biotech and pharma names.\nBiotech has been a laggard this year, gaining big in February and ...</p>\n\n<a href=\"https://www.cnbc.com/2021/05/31/3-stocks-to-watch-as-asco-conference-gets-underway-.html\">Web Link</a>\n\n</div>\n","source":"cnbc_highlight","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Three stocks to watch as a big annual biotech conference gets underway</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nThree stocks to watch as a big annual biotech conference gets underway\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-05-31 21:48 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.cnbc.com/2021/05/31/3-stocks-to-watch-as-asco-conference-gets-underway-.html><strong>CNBC</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The annual ASCO meeting begins at the end of the week, a conference that has often provided a tailwind for biotech and pharma names.\nBiotech has been a laggard this year, gaining big in February and ...</p>\n\n<a href=\"https://www.cnbc.com/2021/05/31/3-stocks-to-watch-as-asco-conference-gets-underway-.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"LLY":"礼来","ABBV":"艾伯维公司","REGN":"再生元制药公司","GILD":"吉利德科学","MRK":"默沙东","HOOK":"Hookipa Pharma Inc"},"source_url":"https://www.cnbc.com/2021/05/31/3-stocks-to-watch-as-asco-conference-gets-underway-.html","is_english":true,"share_image_url":"https://static.laohu8.com/72bb72e1b84c09fca865c6dcb1bbcd16","article_id":"1104481164","content_text":"The annual ASCO meeting begins at the end of the week, a conference that has often provided a tailwind for biotech and pharma names.\nBiotech has been a laggard this year, gaining big in February and March but declining and trading in a choppy range since then.\nBank of America analyst Geoff Meacham identified three companies that could get a positive reception at the meeting.\nThe The American Society of Clinical Oncology meeting will be virtual for a second year, and runs from from June 4 to June 8. Meacham said it is important but ASCO may not provide the pop to stocks it did in other years.\n“ASCO was by far and away the biggest medical conference of the year, and people looked forward to that. And you would have company presentations in front of 30,000 oncologists,” he said. “There would be hundreds of Wall Streeters. You could get a very good handle on what was the buzz of the meeting. SInce it’s virtual, it doesn’t have as much of its charm.”\nBut Meacham said ASCO could still be positive. “You have data that’s brand new and that could lead to approvals and some very good products,” he said.\nMeacham said he’s still positive on biotech despite its lackluster performance. He especially likes mid-cap biotech.\n“We’ve been pretty positive on the group. Recognizing that drug pricing has been a little bit of a cloud over the past couple of years, and 2021 is no different,” said Meacham. “But when you look at the pipeline, the midcap biotech pipeline looks fantastic.”\nThe pipeline in big pharma is got but not as robust. “For the most part, it’s singles and doubles. But not surprisingly, midcap biotech has some home run potential but with more risk. That’s what drives the industry - the innovation and new therapies - and that’s why we’re still positive.”\n\nThe IBB iShares NASDAQ Biotech ETF gained 0.4% last week, but it is up just 0.3% year-to-date. The widely followed IBB was down 1.7% for the month of May.\nMeacham identified three companies that could get a positive reception at the ASCO meeting. Bank of America has a buy rating on all of them. One of those is big pharma Bristol-Myers Squibb.\n“Bristol is probably one of the winners,” he said. The company’s anti-LAG-3 antibody relatlimab melanoma treatment has been in development and there will be data from a large phase 3 trial. He said the product was used with its Opdivo, and could have a better safety profile than the current treatment of Opdivo combined with Yervoy. He does expect Opdivo and Yervoy to maintain the lead share of the market going forward.\nBig cap biotech Amgen is presenting on its lung cancer drug Lumakras, which received Food and Drug Administration approval Friday. The drug was approved to treat lung cancer patients with a genetic mutation known as KRAS. The approval came sooner than expected and sent Amgen shares up more than 1.1% Friday.\nHe said it could be combined with other therapy, like Opdivo. “That two drug combination could be really profound,” he said.\nBiotech company Seagen is going to present on its Padcev treatment for bladder and kidney cancer, launched last year. “This is an update of existing data,” he said. The data shows patients live longer.\nThe study is a small phase 2 trial, but there is another larger phase 3 trial that combines the therapy with Merck’s Keytruda.\nOther companies with data to be presented at ASCO include Eli Lilly,Merck,Regeneron,Hookipa,AbbVie, and Gilead.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":110413794,"gmtCreate":1622479969918,"gmtModify":1704184972192,"author":{"id":"3573427053802677","authorId":"3573427053802677","name":"AlexRach","avatar":"https://static.tigerbbs.com/01fc7c44687a21ec1b63452d2d5964ea","vip":1,"crmLevel":1,"crmLevelSwitch":0,"authorIdStr":"3573427053802677","idStr":"3573427053802677"},"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/110413794","repostId":1104481164,"repostType":4,"repost":{"id":"1104481164","kind":"news","pubTimestamp":1622468928,"share":"https://ttm.financial/m/news/1104481164?lang=&edition=fundamental","pubTime":"2021-05-31 21:48","market":"us","language":"en","title":"Three stocks to watch as a big annual biotech conference gets underway","url":"https://stock-news.laohu8.com/highlight/detail?id=1104481164","media":"CNBC","summary":"The annual ASCO meeting begins at the end of the week, a conference that has often provided a tailwi","content":"<div>\n<p>The annual ASCO meeting begins at the end of the week, a conference that has often provided a tailwind for biotech and pharma names.\nBiotech has been a laggard this year, gaining big in February and ...</p>\n\n<a href=\"https://www.cnbc.com/2021/05/31/3-stocks-to-watch-as-asco-conference-gets-underway-.html\">Web Link</a>\n\n</div>\n","source":"cnbc_highlight","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Three stocks to watch as a big annual biotech conference gets underway</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nThree stocks to watch as a big annual biotech conference gets underway\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-05-31 21:48 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.cnbc.com/2021/05/31/3-stocks-to-watch-as-asco-conference-gets-underway-.html><strong>CNBC</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The annual ASCO meeting begins at the end of the week, a conference that has often provided a tailwind for biotech and pharma names.\nBiotech has been a laggard this year, gaining big in February and ...</p>\n\n<a href=\"https://www.cnbc.com/2021/05/31/3-stocks-to-watch-as-asco-conference-gets-underway-.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"LLY":"礼来","ABBV":"艾伯维公司","REGN":"再生元制药公司","GILD":"吉利德科学","MRK":"默沙东","HOOK":"Hookipa Pharma Inc"},"source_url":"https://www.cnbc.com/2021/05/31/3-stocks-to-watch-as-asco-conference-gets-underway-.html","is_english":true,"share_image_url":"https://static.laohu8.com/72bb72e1b84c09fca865c6dcb1bbcd16","article_id":"1104481164","content_text":"The annual ASCO meeting begins at the end of the week, a conference that has often provided a tailwind for biotech and pharma names.\nBiotech has been a laggard this year, gaining big in February and March but declining and trading in a choppy range since then.\nBank of America analyst Geoff Meacham identified three companies that could get a positive reception at the meeting.\nThe The American Society of Clinical Oncology meeting will be virtual for a second year, and runs from from June 4 to June 8. Meacham said it is important but ASCO may not provide the pop to stocks it did in other years.\n“ASCO was by far and away the biggest medical conference of the year, and people looked forward to that. And you would have company presentations in front of 30,000 oncologists,” he said. “There would be hundreds of Wall Streeters. You could get a very good handle on what was the buzz of the meeting. SInce it’s virtual, it doesn’t have as much of its charm.”\nBut Meacham said ASCO could still be positive. “You have data that’s brand new and that could lead to approvals and some very good products,” he said.\nMeacham said he’s still positive on biotech despite its lackluster performance. He especially likes mid-cap biotech.\n“We’ve been pretty positive on the group. Recognizing that drug pricing has been a little bit of a cloud over the past couple of years, and 2021 is no different,” said Meacham. “But when you look at the pipeline, the midcap biotech pipeline looks fantastic.”\nThe pipeline in big pharma is got but not as robust. “For the most part, it’s singles and doubles. But not surprisingly, midcap biotech has some home run potential but with more risk. That’s what drives the industry - the innovation and new therapies - and that’s why we’re still positive.”\n\nThe IBB iShares NASDAQ Biotech ETF gained 0.4% last week, but it is up just 0.3% year-to-date. The widely followed IBB was down 1.7% for the month of May.\nMeacham identified three companies that could get a positive reception at the ASCO meeting. Bank of America has a buy rating on all of them. One of those is big pharma Bristol-Myers Squibb.\n“Bristol is probably one of the winners,” he said. The company’s anti-LAG-3 antibody relatlimab melanoma treatment has been in development and there will be data from a large phase 3 trial. He said the product was used with its Opdivo, and could have a better safety profile than the current treatment of Opdivo combined with Yervoy. He does expect Opdivo and Yervoy to maintain the lead share of the market going forward.\nBig cap biotech Amgen is presenting on its lung cancer drug Lumakras, which received Food and Drug Administration approval Friday. The drug was approved to treat lung cancer patients with a genetic mutation known as KRAS. The approval came sooner than expected and sent Amgen shares up more than 1.1% Friday.\nHe said it could be combined with other therapy, like Opdivo. “That two drug combination could be really profound,” he said.\nBiotech company Seagen is going to present on its Padcev treatment for bladder and kidney cancer, launched last year. “This is an update of existing data,” he said. The data shows patients live longer.\nThe study is a small phase 2 trial, but there is another larger phase 3 trial that combines the therapy with Merck’s Keytruda.\nOther companies with data to be presented at ASCO include Eli Lilly,Merck,Regeneron,Hookipa,AbbVie, and Gilead.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":4520682,"gmtCreate":1622500267733,"gmtModify":1680792230994,"authorId":3581996355402655,"author":{"id":3581996355402655,"idStr":"3581996355402655","authorId":3581996355402655,"name":"LiuQY","avatar":"https://static.tigerbbs.com/675aff70b593df96675c1c39cf1bbae0","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":110413794,"type":1,"supId":0,"prevId":0,"content":"To the moom","text":"To the moom","html":"To the moom"}],"langContent":"EN"},{"id":110436875,"gmtCreate":1622478305397,"gmtModify":1704184962328,"author":{"id":"3581068447827734","authorId":"3581068447827734","name":"chloectf","avatar":"https://static.tigerbbs.com/06d56a93f739ead7167ceebacde7e1e6","vip":1,"crmLevel":4,"crmLevelSwitch":0,"authorIdStr":"3581068447827734","idStr":"3581068447827734"},"htmlText":"Always interesting to learn about these more niche&nbsp;companies ?","listText":"Always interesting to learn about these more niche&nbsp;companies ?","text":"Always interesting to learn about these more niche companies ?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":2,"repostSize":0,"link":"https://ttm.financial/post/110436875","repostId":1104481164,"repostType":4,"repost":{"id":"1104481164","kind":"news","pubTimestamp":1622468928,"share":"https://ttm.financial/m/news/1104481164?lang=&edition=fundamental","pubTime":"2021-05-31 21:48","market":"us","language":"en","title":"Three stocks to watch as a big annual biotech conference gets underway","url":"https://stock-news.laohu8.com/highlight/detail?id=1104481164","media":"CNBC","summary":"The annual ASCO meeting begins at the end of the week, a conference that has often provided a tailwi","content":"<div>\n<p>The annual ASCO meeting begins at the end of the week, a conference that has often provided a tailwind for biotech and pharma names.\nBiotech has been a laggard this year, gaining big in February and ...</p>\n\n<a href=\"https://www.cnbc.com/2021/05/31/3-stocks-to-watch-as-asco-conference-gets-underway-.html\">Web Link</a>\n\n</div>\n","source":"cnbc_highlight","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Three stocks to watch as a big annual biotech conference gets underway</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nThree stocks to watch as a big annual biotech conference gets underway\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-05-31 21:48 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.cnbc.com/2021/05/31/3-stocks-to-watch-as-asco-conference-gets-underway-.html><strong>CNBC</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The annual ASCO meeting begins at the end of the week, a conference that has often provided a tailwind for biotech and pharma names.\nBiotech has been a laggard this year, gaining big in February and ...</p>\n\n<a href=\"https://www.cnbc.com/2021/05/31/3-stocks-to-watch-as-asco-conference-gets-underway-.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"LLY":"礼来","ABBV":"艾伯维公司","REGN":"再生元制药公司","GILD":"吉利德科学","MRK":"默沙东","HOOK":"Hookipa Pharma Inc"},"source_url":"https://www.cnbc.com/2021/05/31/3-stocks-to-watch-as-asco-conference-gets-underway-.html","is_english":true,"share_image_url":"https://static.laohu8.com/72bb72e1b84c09fca865c6dcb1bbcd16","article_id":"1104481164","content_text":"The annual ASCO meeting begins at the end of the week, a conference that has often provided a tailwind for biotech and pharma names.\nBiotech has been a laggard this year, gaining big in February and March but declining and trading in a choppy range since then.\nBank of America analyst Geoff Meacham identified three companies that could get a positive reception at the meeting.\nThe The American Society of Clinical Oncology meeting will be virtual for a second year, and runs from from June 4 to June 8. Meacham said it is important but ASCO may not provide the pop to stocks it did in other years.\n“ASCO was by far and away the biggest medical conference of the year, and people looked forward to that. And you would have company presentations in front of 30,000 oncologists,” he said. “There would be hundreds of Wall Streeters. You could get a very good handle on what was the buzz of the meeting. SInce it’s virtual, it doesn’t have as much of its charm.”\nBut Meacham said ASCO could still be positive. “You have data that’s brand new and that could lead to approvals and some very good products,” he said.\nMeacham said he’s still positive on biotech despite its lackluster performance. He especially likes mid-cap biotech.\n“We’ve been pretty positive on the group. Recognizing that drug pricing has been a little bit of a cloud over the past couple of years, and 2021 is no different,” said Meacham. “But when you look at the pipeline, the midcap biotech pipeline looks fantastic.”\nThe pipeline in big pharma is got but not as robust. “For the most part, it’s singles and doubles. But not surprisingly, midcap biotech has some home run potential but with more risk. That’s what drives the industry - the innovation and new therapies - and that’s why we’re still positive.”\n\nThe IBB iShares NASDAQ Biotech ETF gained 0.4% last week, but it is up just 0.3% year-to-date. The widely followed IBB was down 1.7% for the month of May.\nMeacham identified three companies that could get a positive reception at the ASCO meeting. Bank of America has a buy rating on all of them. One of those is big pharma Bristol-Myers Squibb.\n“Bristol is probably one of the winners,” he said. The company’s anti-LAG-3 antibody relatlimab melanoma treatment has been in development and there will be data from a large phase 3 trial. He said the product was used with its Opdivo, and could have a better safety profile than the current treatment of Opdivo combined with Yervoy. He does expect Opdivo and Yervoy to maintain the lead share of the market going forward.\nBig cap biotech Amgen is presenting on its lung cancer drug Lumakras, which received Food and Drug Administration approval Friday. The drug was approved to treat lung cancer patients with a genetic mutation known as KRAS. The approval came sooner than expected and sent Amgen shares up more than 1.1% Friday.\nHe said it could be combined with other therapy, like Opdivo. “That two drug combination could be really profound,” he said.\nBiotech company Seagen is going to present on its Padcev treatment for bladder and kidney cancer, launched last year. “This is an update of existing data,” he said. The data shows patients live longer.\nThe study is a small phase 2 trial, but there is another larger phase 3 trial that combines the therapy with Merck’s Keytruda.\nOther companies with data to be presented at ASCO include Eli Lilly,Merck,Regeneron,Hookipa,AbbVie, and Gilead.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":4520068,"gmtCreate":1622478478131,"gmtModify":1680792218193,"authorId":3584427150211262,"author":{"id":3584427150211262,"idStr":"3584427150211262","authorId":3584427150211262,"name":"yesssuu","avatar":"https://static.tigerbbs.com/24aa552e605d099ae8a1fd10a0f26ebd","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":110436875,"type":1,"supId":0,"prevId":0,"content":"nice","text":"nice","html":"nice"},{"id":4520147,"gmtCreate":1622480427729,"gmtModify":1680792218112,"authorId":3571893886885807,"author":{"id":3571893886885807,"idStr":"3571893886885807","authorId":3571893886885807,"name":"jaswsf","avatar":"https://static.tigerbbs.com/ed600b3aaba5cb409e893412ae0ee2a9","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":110436875,"type":1,"supId":0,"prevId":0,"content":"[强] [OK]","text":"[强] [OK]","html":"[强] [OK]"}],"langContent":"EN"},{"id":110433493,"gmtCreate":1622477665912,"gmtModify":1704184958446,"author":{"id":"3555014251535651","authorId":"3555014251535651","name":"Dollarvan","avatar":"https://static.tigerbbs.com/0316ab12b442ee2cd79936de06de5089","vip":1,"crmLevel":5,"crmLevelSwitch":1,"authorIdStr":"3555014251535651","idStr":"3555014251535651"},"htmlText":"Like n comment","listText":"Like n comment","text":"Like n comment","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/110433493","repostId":1104481164,"repostType":4,"repost":{"id":"1104481164","kind":"news","pubTimestamp":1622468928,"share":"https://ttm.financial/m/news/1104481164?lang=&edition=fundamental","pubTime":"2021-05-31 21:48","market":"us","language":"en","title":"Three stocks to watch as a big annual biotech conference gets underway","url":"https://stock-news.laohu8.com/highlight/detail?id=1104481164","media":"CNBC","summary":"The annual ASCO meeting begins at the end of the week, a conference that has often provided a tailwi","content":"<div>\n<p>The annual ASCO meeting begins at the end of the week, a conference that has often provided a tailwind for biotech and pharma names.\nBiotech has been a laggard this year, gaining big in February and ...</p>\n\n<a href=\"https://www.cnbc.com/2021/05/31/3-stocks-to-watch-as-asco-conference-gets-underway-.html\">Web Link</a>\n\n</div>\n","source":"cnbc_highlight","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Three stocks to watch as a big annual biotech conference gets underway</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nThree stocks to watch as a big annual biotech conference gets underway\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-05-31 21:48 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.cnbc.com/2021/05/31/3-stocks-to-watch-as-asco-conference-gets-underway-.html><strong>CNBC</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The annual ASCO meeting begins at the end of the week, a conference that has often provided a tailwind for biotech and pharma names.\nBiotech has been a laggard this year, gaining big in February and ...</p>\n\n<a href=\"https://www.cnbc.com/2021/05/31/3-stocks-to-watch-as-asco-conference-gets-underway-.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"LLY":"礼来","ABBV":"艾伯维公司","REGN":"再生元制药公司","GILD":"吉利德科学","MRK":"默沙东","HOOK":"Hookipa Pharma Inc"},"source_url":"https://www.cnbc.com/2021/05/31/3-stocks-to-watch-as-asco-conference-gets-underway-.html","is_english":true,"share_image_url":"https://static.laohu8.com/72bb72e1b84c09fca865c6dcb1bbcd16","article_id":"1104481164","content_text":"The annual ASCO meeting begins at the end of the week, a conference that has often provided a tailwind for biotech and pharma names.\nBiotech has been a laggard this year, gaining big in February and March but declining and trading in a choppy range since then.\nBank of America analyst Geoff Meacham identified three companies that could get a positive reception at the meeting.\nThe The American Society of Clinical Oncology meeting will be virtual for a second year, and runs from from June 4 to June 8. Meacham said it is important but ASCO may not provide the pop to stocks it did in other years.\n“ASCO was by far and away the biggest medical conference of the year, and people looked forward to that. And you would have company presentations in front of 30,000 oncologists,” he said. “There would be hundreds of Wall Streeters. You could get a very good handle on what was the buzz of the meeting. SInce it’s virtual, it doesn’t have as much of its charm.”\nBut Meacham said ASCO could still be positive. “You have data that’s brand new and that could lead to approvals and some very good products,” he said.\nMeacham said he’s still positive on biotech despite its lackluster performance. He especially likes mid-cap biotech.\n“We’ve been pretty positive on the group. Recognizing that drug pricing has been a little bit of a cloud over the past couple of years, and 2021 is no different,” said Meacham. “But when you look at the pipeline, the midcap biotech pipeline looks fantastic.”\nThe pipeline in big pharma is got but not as robust. “For the most part, it’s singles and doubles. But not surprisingly, midcap biotech has some home run potential but with more risk. That’s what drives the industry - the innovation and new therapies - and that’s why we’re still positive.”\n\nThe IBB iShares NASDAQ Biotech ETF gained 0.4% last week, but it is up just 0.3% year-to-date. The widely followed IBB was down 1.7% for the month of May.\nMeacham identified three companies that could get a positive reception at the ASCO meeting. Bank of America has a buy rating on all of them. One of those is big pharma Bristol-Myers Squibb.\n“Bristol is probably one of the winners,” he said. The company’s anti-LAG-3 antibody relatlimab melanoma treatment has been in development and there will be data from a large phase 3 trial. He said the product was used with its Opdivo, and could have a better safety profile than the current treatment of Opdivo combined with Yervoy. He does expect Opdivo and Yervoy to maintain the lead share of the market going forward.\nBig cap biotech Amgen is presenting on its lung cancer drug Lumakras, which received Food and Drug Administration approval Friday. The drug was approved to treat lung cancer patients with a genetic mutation known as KRAS. The approval came sooner than expected and sent Amgen shares up more than 1.1% Friday.\nHe said it could be combined with other therapy, like Opdivo. “That two drug combination could be really profound,” he said.\nBiotech company Seagen is going to present on its Padcev treatment for bladder and kidney cancer, launched last year. “This is an update of existing data,” he said. The data shows patients live longer.\nThe study is a small phase 2 trial, but there is another larger phase 3 trial that combines the therapy with Merck’s Keytruda.\nOther companies with data to be presented at ASCO include Eli Lilly,Merck,Regeneron,Hookipa,AbbVie, and Gilead.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":4526312,"gmtCreate":1622522243920,"gmtModify":1680792332050,"authorId":3580629550243320,"author":{"id":3580629550243320,"idStr":"3580629550243320","authorId":3580629550243320,"name":"小小馒头","avatar":"https://static.tigerbbs.com/8662af09a6a7d2e9548f6a2e76832bc6","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":110433493,"type":1,"supId":0,"prevId":0,"content":"Sure boss!","text":"Sure boss!","html":"Sure boss!"}],"langContent":"EN"},{"id":110495137,"gmtCreate":1622476746029,"gmtModify":1704184950459,"author":{"id":"3577412131413749","authorId":"3577412131413749","name":"TWKF","avatar":"https://static.tigerbbs.com/fdb0a0780234743b05dc799f02262c11","vip":1,"crmLevel":2,"crmLevelSwitch":0,"authorIdStr":"3577412131413749","idStr":"3577412131413749"},"htmlText":"Yes","listText":"Yes","text":"Yes","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/110495137","repostId":1104481164,"repostType":4,"repost":{"id":"1104481164","kind":"news","pubTimestamp":1622468928,"share":"https://ttm.financial/m/news/1104481164?lang=&edition=fundamental","pubTime":"2021-05-31 21:48","market":"us","language":"en","title":"Three stocks to watch as a big annual biotech conference gets underway","url":"https://stock-news.laohu8.com/highlight/detail?id=1104481164","media":"CNBC","summary":"The annual ASCO meeting begins at the end of the week, a conference that has often provided a tailwi","content":"<div>\n<p>The annual ASCO meeting begins at the end of the week, a conference that has often provided a tailwind for biotech and pharma names.\nBiotech has been a laggard this year, gaining big in February and ...</p>\n\n<a href=\"https://www.cnbc.com/2021/05/31/3-stocks-to-watch-as-asco-conference-gets-underway-.html\">Web Link</a>\n\n</div>\n","source":"cnbc_highlight","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Three stocks to watch as a big annual biotech conference gets underway</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nThree stocks to watch as a big annual biotech conference gets underway\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-05-31 21:48 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.cnbc.com/2021/05/31/3-stocks-to-watch-as-asco-conference-gets-underway-.html><strong>CNBC</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The annual ASCO meeting begins at the end of the week, a conference that has often provided a tailwind for biotech and pharma names.\nBiotech has been a laggard this year, gaining big in February and ...</p>\n\n<a href=\"https://www.cnbc.com/2021/05/31/3-stocks-to-watch-as-asco-conference-gets-underway-.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"LLY":"礼来","ABBV":"艾伯维公司","REGN":"再生元制药公司","GILD":"吉利德科学","MRK":"默沙东","HOOK":"Hookipa Pharma Inc"},"source_url":"https://www.cnbc.com/2021/05/31/3-stocks-to-watch-as-asco-conference-gets-underway-.html","is_english":true,"share_image_url":"https://static.laohu8.com/72bb72e1b84c09fca865c6dcb1bbcd16","article_id":"1104481164","content_text":"The annual ASCO meeting begins at the end of the week, a conference that has often provided a tailwind for biotech and pharma names.\nBiotech has been a laggard this year, gaining big in February and March but declining and trading in a choppy range since then.\nBank of America analyst Geoff Meacham identified three companies that could get a positive reception at the meeting.\nThe The American Society of Clinical Oncology meeting will be virtual for a second year, and runs from from June 4 to June 8. Meacham said it is important but ASCO may not provide the pop to stocks it did in other years.\n“ASCO was by far and away the biggest medical conference of the year, and people looked forward to that. And you would have company presentations in front of 30,000 oncologists,” he said. “There would be hundreds of Wall Streeters. You could get a very good handle on what was the buzz of the meeting. SInce it’s virtual, it doesn’t have as much of its charm.”\nBut Meacham said ASCO could still be positive. “You have data that’s brand new and that could lead to approvals and some very good products,” he said.\nMeacham said he’s still positive on biotech despite its lackluster performance. He especially likes mid-cap biotech.\n“We’ve been pretty positive on the group. Recognizing that drug pricing has been a little bit of a cloud over the past couple of years, and 2021 is no different,” said Meacham. “But when you look at the pipeline, the midcap biotech pipeline looks fantastic.”\nThe pipeline in big pharma is got but not as robust. “For the most part, it’s singles and doubles. But not surprisingly, midcap biotech has some home run potential but with more risk. That’s what drives the industry - the innovation and new therapies - and that’s why we’re still positive.”\n\nThe IBB iShares NASDAQ Biotech ETF gained 0.4% last week, but it is up just 0.3% year-to-date. The widely followed IBB was down 1.7% for the month of May.\nMeacham identified three companies that could get a positive reception at the ASCO meeting. Bank of America has a buy rating on all of them. One of those is big pharma Bristol-Myers Squibb.\n“Bristol is probably one of the winners,” he said. The company’s anti-LAG-3 antibody relatlimab melanoma treatment has been in development and there will be data from a large phase 3 trial. He said the product was used with its Opdivo, and could have a better safety profile than the current treatment of Opdivo combined with Yervoy. He does expect Opdivo and Yervoy to maintain the lead share of the market going forward.\nBig cap biotech Amgen is presenting on its lung cancer drug Lumakras, which received Food and Drug Administration approval Friday. The drug was approved to treat lung cancer patients with a genetic mutation known as KRAS. The approval came sooner than expected and sent Amgen shares up more than 1.1% Friday.\nHe said it could be combined with other therapy, like Opdivo. “That two drug combination could be really profound,” he said.\nBiotech company Seagen is going to present on its Padcev treatment for bladder and kidney cancer, launched last year. “This is an update of existing data,” he said. The data shows patients live longer.\nThe study is a small phase 2 trial, but there is another larger phase 3 trial that combines the therapy with Merck’s Keytruda.\nOther companies with data to be presented at ASCO include Eli Lilly,Merck,Regeneron,Hookipa,AbbVie, and Gilead.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":110498572,"gmtCreate":1622476375196,"gmtModify":1704184947343,"author":{"id":"3560902410034010","authorId":"3560902410034010","name":"chiin","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":2,"crmLevelSwitch":0,"authorIdStr":"3560902410034010","idStr":"3560902410034010"},"htmlText":"Yes","listText":"Yes","text":"Yes","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":2,"repostSize":0,"link":"https://ttm.financial/post/110498572","repostId":1104481164,"repostType":4,"repost":{"id":"1104481164","kind":"news","pubTimestamp":1622468928,"share":"https://ttm.financial/m/news/1104481164?lang=&edition=fundamental","pubTime":"2021-05-31 21:48","market":"us","language":"en","title":"Three stocks to watch as a big annual biotech conference gets underway","url":"https://stock-news.laohu8.com/highlight/detail?id=1104481164","media":"CNBC","summary":"The annual ASCO meeting begins at the end of the week, a conference that has often provided a tailwi","content":"<div>\n<p>The annual ASCO meeting begins at the end of the week, a conference that has often provided a tailwind for biotech and pharma names.\nBiotech has been a laggard this year, gaining big in February and ...</p>\n\n<a href=\"https://www.cnbc.com/2021/05/31/3-stocks-to-watch-as-asco-conference-gets-underway-.html\">Web Link</a>\n\n</div>\n","source":"cnbc_highlight","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Three stocks to watch as a big annual biotech conference gets underway</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nThree stocks to watch as a big annual biotech conference gets underway\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-05-31 21:48 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.cnbc.com/2021/05/31/3-stocks-to-watch-as-asco-conference-gets-underway-.html><strong>CNBC</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The annual ASCO meeting begins at the end of the week, a conference that has often provided a tailwind for biotech and pharma names.\nBiotech has been a laggard this year, gaining big in February and ...</p>\n\n<a href=\"https://www.cnbc.com/2021/05/31/3-stocks-to-watch-as-asco-conference-gets-underway-.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"LLY":"礼来","ABBV":"艾伯维公司","REGN":"再生元制药公司","GILD":"吉利德科学","MRK":"默沙东","HOOK":"Hookipa Pharma Inc"},"source_url":"https://www.cnbc.com/2021/05/31/3-stocks-to-watch-as-asco-conference-gets-underway-.html","is_english":true,"share_image_url":"https://static.laohu8.com/72bb72e1b84c09fca865c6dcb1bbcd16","article_id":"1104481164","content_text":"The annual ASCO meeting begins at the end of the week, a conference that has often provided a tailwind for biotech and pharma names.\nBiotech has been a laggard this year, gaining big in February and March but declining and trading in a choppy range since then.\nBank of America analyst Geoff Meacham identified three companies that could get a positive reception at the meeting.\nThe The American Society of Clinical Oncology meeting will be virtual for a second year, and runs from from June 4 to June 8. Meacham said it is important but ASCO may not provide the pop to stocks it did in other years.\n“ASCO was by far and away the biggest medical conference of the year, and people looked forward to that. And you would have company presentations in front of 30,000 oncologists,” he said. “There would be hundreds of Wall Streeters. You could get a very good handle on what was the buzz of the meeting. SInce it’s virtual, it doesn’t have as much of its charm.”\nBut Meacham said ASCO could still be positive. “You have data that’s brand new and that could lead to approvals and some very good products,” he said.\nMeacham said he’s still positive on biotech despite its lackluster performance. He especially likes mid-cap biotech.\n“We’ve been pretty positive on the group. Recognizing that drug pricing has been a little bit of a cloud over the past couple of years, and 2021 is no different,” said Meacham. “But when you look at the pipeline, the midcap biotech pipeline looks fantastic.”\nThe pipeline in big pharma is got but not as robust. “For the most part, it’s singles and doubles. But not surprisingly, midcap biotech has some home run potential but with more risk. That’s what drives the industry - the innovation and new therapies - and that’s why we’re still positive.”\n\nThe IBB iShares NASDAQ Biotech ETF gained 0.4% last week, but it is up just 0.3% year-to-date. The widely followed IBB was down 1.7% for the month of May.\nMeacham identified three companies that could get a positive reception at the ASCO meeting. Bank of America has a buy rating on all of them. One of those is big pharma Bristol-Myers Squibb.\n“Bristol is probably one of the winners,” he said. The company’s anti-LAG-3 antibody relatlimab melanoma treatment has been in development and there will be data from a large phase 3 trial. He said the product was used with its Opdivo, and could have a better safety profile than the current treatment of Opdivo combined with Yervoy. He does expect Opdivo and Yervoy to maintain the lead share of the market going forward.\nBig cap biotech Amgen is presenting on its lung cancer drug Lumakras, which received Food and Drug Administration approval Friday. The drug was approved to treat lung cancer patients with a genetic mutation known as KRAS. The approval came sooner than expected and sent Amgen shares up more than 1.1% Friday.\nHe said it could be combined with other therapy, like Opdivo. “That two drug combination could be really profound,” he said.\nBiotech company Seagen is going to present on its Padcev treatment for bladder and kidney cancer, launched last year. “This is an update of existing data,” he said. The data shows patients live longer.\nThe study is a small phase 2 trial, but there is another larger phase 3 trial that combines the therapy with Merck’s Keytruda.\nOther companies with data to be presented at ASCO include Eli Lilly,Merck,Regeneron,Hookipa,AbbVie, and Gilead.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":4519958,"gmtCreate":1622476489109,"gmtModify":1680792211244,"authorId":3560902410034010,"author":{"id":3560902410034010,"idStr":"3560902410034010","authorId":3560902410034010,"name":"chiin","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":110498572,"type":1,"supId":4519955,"prevId":0,"content":"?","text":"?","html":"?"},{"id":4519955,"gmtCreate":1622476421441,"gmtModify":1680792209044,"authorId":3556768594543699,"author":{"id":3556768594543699,"idStr":"3556768594543699","authorId":3556768594543699,"name":"AshleyKinson","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":3,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":110498572,"type":1,"supId":0,"prevId":0,"content":"<u>ok</u>","text":"<u>ok</u>","html":"<u>ok</u>"}],"langContent":"EN"},{"id":110498842,"gmtCreate":1622476355886,"gmtModify":1704184946524,"author":{"id":"3556768594543699","authorId":"3556768594543699","name":"AshleyKinson","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":3,"crmLevelSwitch":0,"authorIdStr":"3556768594543699","idStr":"3556768594543699"},"htmlText":"3?","listText":"3?","text":"3?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/110498842","repostId":1104481164,"repostType":4,"repost":{"id":"1104481164","kind":"news","pubTimestamp":1622468928,"share":"https://ttm.financial/m/news/1104481164?lang=&edition=fundamental","pubTime":"2021-05-31 21:48","market":"us","language":"en","title":"Three stocks to watch as a big annual biotech conference gets underway","url":"https://stock-news.laohu8.com/highlight/detail?id=1104481164","media":"CNBC","summary":"The annual ASCO meeting begins at the end of the week, a conference that has often provided a tailwi","content":"<div>\n<p>The annual ASCO meeting begins at the end of the week, a conference that has often provided a tailwind for biotech and pharma names.\nBiotech has been a laggard this year, gaining big in February and ...</p>\n\n<a href=\"https://www.cnbc.com/2021/05/31/3-stocks-to-watch-as-asco-conference-gets-underway-.html\">Web Link</a>\n\n</div>\n","source":"cnbc_highlight","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Three stocks to watch as a big annual biotech conference gets underway</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nThree stocks to watch as a big annual biotech conference gets underway\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-05-31 21:48 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.cnbc.com/2021/05/31/3-stocks-to-watch-as-asco-conference-gets-underway-.html><strong>CNBC</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The annual ASCO meeting begins at the end of the week, a conference that has often provided a tailwind for biotech and pharma names.\nBiotech has been a laggard this year, gaining big in February and ...</p>\n\n<a href=\"https://www.cnbc.com/2021/05/31/3-stocks-to-watch-as-asco-conference-gets-underway-.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"LLY":"礼来","ABBV":"艾伯维公司","REGN":"再生元制药公司","GILD":"吉利德科学","MRK":"默沙东","HOOK":"Hookipa Pharma Inc"},"source_url":"https://www.cnbc.com/2021/05/31/3-stocks-to-watch-as-asco-conference-gets-underway-.html","is_english":true,"share_image_url":"https://static.laohu8.com/72bb72e1b84c09fca865c6dcb1bbcd16","article_id":"1104481164","content_text":"The annual ASCO meeting begins at the end of the week, a conference that has often provided a tailwind for biotech and pharma names.\nBiotech has been a laggard this year, gaining big in February and March but declining and trading in a choppy range since then.\nBank of America analyst Geoff Meacham identified three companies that could get a positive reception at the meeting.\nThe The American Society of Clinical Oncology meeting will be virtual for a second year, and runs from from June 4 to June 8. Meacham said it is important but ASCO may not provide the pop to stocks it did in other years.\n“ASCO was by far and away the biggest medical conference of the year, and people looked forward to that. And you would have company presentations in front of 30,000 oncologists,” he said. “There would be hundreds of Wall Streeters. You could get a very good handle on what was the buzz of the meeting. SInce it’s virtual, it doesn’t have as much of its charm.”\nBut Meacham said ASCO could still be positive. “You have data that’s brand new and that could lead to approvals and some very good products,” he said.\nMeacham said he’s still positive on biotech despite its lackluster performance. He especially likes mid-cap biotech.\n“We’ve been pretty positive on the group. Recognizing that drug pricing has been a little bit of a cloud over the past couple of years, and 2021 is no different,” said Meacham. “But when you look at the pipeline, the midcap biotech pipeline looks fantastic.”\nThe pipeline in big pharma is got but not as robust. “For the most part, it’s singles and doubles. But not surprisingly, midcap biotech has some home run potential but with more risk. That’s what drives the industry - the innovation and new therapies - and that’s why we’re still positive.”\n\nThe IBB iShares NASDAQ Biotech ETF gained 0.4% last week, but it is up just 0.3% year-to-date. The widely followed IBB was down 1.7% for the month of May.\nMeacham identified three companies that could get a positive reception at the ASCO meeting. Bank of America has a buy rating on all of them. One of those is big pharma Bristol-Myers Squibb.\n“Bristol is probably one of the winners,” he said. The company’s anti-LAG-3 antibody relatlimab melanoma treatment has been in development and there will be data from a large phase 3 trial. He said the product was used with its Opdivo, and could have a better safety profile than the current treatment of Opdivo combined with Yervoy. He does expect Opdivo and Yervoy to maintain the lead share of the market going forward.\nBig cap biotech Amgen is presenting on its lung cancer drug Lumakras, which received Food and Drug Administration approval Friday. The drug was approved to treat lung cancer patients with a genetic mutation known as KRAS. The approval came sooner than expected and sent Amgen shares up more than 1.1% Friday.\nHe said it could be combined with other therapy, like Opdivo. “That two drug combination could be really profound,” he said.\nBiotech company Seagen is going to present on its Padcev treatment for bladder and kidney cancer, launched last year. “This is an update of existing data,” he said. The data shows patients live longer.\nThe study is a small phase 2 trial, but there is another larger phase 3 trial that combines the therapy with Merck’s Keytruda.\nOther companies with data to be presented at ASCO include Eli Lilly,Merck,Regeneron,Hookipa,AbbVie, and Gilead.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":4519957,"gmtCreate":1622476449120,"gmtModify":1680792209818,"authorId":3560902410034010,"author":{"id":3560902410034010,"idStr":"3560902410034010","authorId":3560902410034010,"name":"chiin","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":110498842,"type":1,"supId":0,"prevId":0,"content":"Yes itsay","text":"Yes itsay","html":"Yes itsay"}],"langContent":"EN"},{"id":110490252,"gmtCreate":1622475872576,"gmtModify":1704184942262,"author":{"id":"3574817325947403","authorId":"3574817325947403","name":"tangtkh","avatar":"https://static.tigerbbs.com/d9ad77ea495b2bbbfb9c10734b6f2fb0","vip":1,"crmLevel":6,"crmLevelSwitch":0,"authorIdStr":"3574817325947403","idStr":"3574817325947403"},"htmlText":"Watch","listText":"Watch","text":"Watch","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/110490252","repostId":1104481164,"repostType":4,"repost":{"id":"1104481164","kind":"news","pubTimestamp":1622468928,"share":"https://ttm.financial/m/news/1104481164?lang=&edition=fundamental","pubTime":"2021-05-31 21:48","market":"us","language":"en","title":"Three stocks to watch as a big annual biotech conference gets underway","url":"https://stock-news.laohu8.com/highlight/detail?id=1104481164","media":"CNBC","summary":"The annual ASCO meeting begins at the end of the week, a conference that has often provided a tailwi","content":"<div>\n<p>The annual ASCO meeting begins at the end of the week, a conference that has often provided a tailwind for biotech and pharma names.\nBiotech has been a laggard this year, gaining big in February and ...</p>\n\n<a href=\"https://www.cnbc.com/2021/05/31/3-stocks-to-watch-as-asco-conference-gets-underway-.html\">Web Link</a>\n\n</div>\n","source":"cnbc_highlight","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Three stocks to watch as a big annual biotech conference gets underway</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nThree stocks to watch as a big annual biotech conference gets underway\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-05-31 21:48 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.cnbc.com/2021/05/31/3-stocks-to-watch-as-asco-conference-gets-underway-.html><strong>CNBC</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The annual ASCO meeting begins at the end of the week, a conference that has often provided a tailwind for biotech and pharma names.\nBiotech has been a laggard this year, gaining big in February and ...</p>\n\n<a href=\"https://www.cnbc.com/2021/05/31/3-stocks-to-watch-as-asco-conference-gets-underway-.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"LLY":"礼来","ABBV":"艾伯维公司","REGN":"再生元制药公司","GILD":"吉利德科学","MRK":"默沙东","HOOK":"Hookipa Pharma Inc"},"source_url":"https://www.cnbc.com/2021/05/31/3-stocks-to-watch-as-asco-conference-gets-underway-.html","is_english":true,"share_image_url":"https://static.laohu8.com/72bb72e1b84c09fca865c6dcb1bbcd16","article_id":"1104481164","content_text":"The annual ASCO meeting begins at the end of the week, a conference that has often provided a tailwind for biotech and pharma names.\nBiotech has been a laggard this year, gaining big in February and March but declining and trading in a choppy range since then.\nBank of America analyst Geoff Meacham identified three companies that could get a positive reception at the meeting.\nThe The American Society of Clinical Oncology meeting will be virtual for a second year, and runs from from June 4 to June 8. Meacham said it is important but ASCO may not provide the pop to stocks it did in other years.\n“ASCO was by far and away the biggest medical conference of the year, and people looked forward to that. And you would have company presentations in front of 30,000 oncologists,” he said. “There would be hundreds of Wall Streeters. You could get a very good handle on what was the buzz of the meeting. SInce it’s virtual, it doesn’t have as much of its charm.”\nBut Meacham said ASCO could still be positive. “You have data that’s brand new and that could lead to approvals and some very good products,” he said.\nMeacham said he’s still positive on biotech despite its lackluster performance. He especially likes mid-cap biotech.\n“We’ve been pretty positive on the group. Recognizing that drug pricing has been a little bit of a cloud over the past couple of years, and 2021 is no different,” said Meacham. “But when you look at the pipeline, the midcap biotech pipeline looks fantastic.”\nThe pipeline in big pharma is got but not as robust. “For the most part, it’s singles and doubles. But not surprisingly, midcap biotech has some home run potential but with more risk. That’s what drives the industry - the innovation and new therapies - and that’s why we’re still positive.”\n\nThe IBB iShares NASDAQ Biotech ETF gained 0.4% last week, but it is up just 0.3% year-to-date. The widely followed IBB was down 1.7% for the month of May.\nMeacham identified three companies that could get a positive reception at the ASCO meeting. Bank of America has a buy rating on all of them. One of those is big pharma Bristol-Myers Squibb.\n“Bristol is probably one of the winners,” he said. The company’s anti-LAG-3 antibody relatlimab melanoma treatment has been in development and there will be data from a large phase 3 trial. He said the product was used with its Opdivo, and could have a better safety profile than the current treatment of Opdivo combined with Yervoy. He does expect Opdivo and Yervoy to maintain the lead share of the market going forward.\nBig cap biotech Amgen is presenting on its lung cancer drug Lumakras, which received Food and Drug Administration approval Friday. The drug was approved to treat lung cancer patients with a genetic mutation known as KRAS. The approval came sooner than expected and sent Amgen shares up more than 1.1% Friday.\nHe said it could be combined with other therapy, like Opdivo. “That two drug combination could be really profound,” he said.\nBiotech company Seagen is going to present on its Padcev treatment for bladder and kidney cancer, launched last year. “This is an update of existing data,” he said. The data shows patients live longer.\nThe study is a small phase 2 trial, but there is another larger phase 3 trial that combines the therapy with Merck’s Keytruda.\nOther companies with data to be presented at ASCO include Eli Lilly,Merck,Regeneron,Hookipa,AbbVie, and Gilead.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":4519946,"gmtCreate":1622476367749,"gmtModify":1680792210090,"authorId":3556768594543699,"author":{"id":3556768594543699,"idStr":"3556768594543699","authorId":3556768594543699,"name":"AshleyKinson","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":3,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":110490252,"type":1,"supId":0,"prevId":0,"content":"<u>what</u>","text":"<u>what</u>","html":"<u>what</u>"}],"langContent":"EN"},{"id":110404642,"gmtCreate":1622475594586,"gmtModify":1704184938958,"author":{"id":"3580781168235968","authorId":"3580781168235968","name":"ShashaRenz","avatar":"https://static.tigerbbs.com/4286a1a0f6a106cf128d7cf92139dcb9","vip":1,"crmLevel":2,"crmLevelSwitch":0,"authorIdStr":"3580781168235968","idStr":"3580781168235968"},"htmlText":"Like please","listText":"Like please","text":"Like please","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/110404642","repostId":1104481164,"repostType":4,"repost":{"id":"1104481164","kind":"news","pubTimestamp":1622468928,"share":"https://ttm.financial/m/news/1104481164?lang=&edition=fundamental","pubTime":"2021-05-31 21:48","market":"us","language":"en","title":"Three stocks to watch as a big annual biotech conference gets underway","url":"https://stock-news.laohu8.com/highlight/detail?id=1104481164","media":"CNBC","summary":"The annual ASCO meeting begins at the end of the week, a conference that has often provided a tailwi","content":"<div>\n<p>The annual ASCO meeting begins at the end of the week, a conference that has often provided a tailwind for biotech and pharma names.\nBiotech has been a laggard this year, gaining big in February and ...</p>\n\n<a href=\"https://www.cnbc.com/2021/05/31/3-stocks-to-watch-as-asco-conference-gets-underway-.html\">Web Link</a>\n\n</div>\n","source":"cnbc_highlight","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Three stocks to watch as a big annual biotech conference gets underway</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nThree stocks to watch as a big annual biotech conference gets underway\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-05-31 21:48 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.cnbc.com/2021/05/31/3-stocks-to-watch-as-asco-conference-gets-underway-.html><strong>CNBC</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The annual ASCO meeting begins at the end of the week, a conference that has often provided a tailwind for biotech and pharma names.\nBiotech has been a laggard this year, gaining big in February and ...</p>\n\n<a href=\"https://www.cnbc.com/2021/05/31/3-stocks-to-watch-as-asco-conference-gets-underway-.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"LLY":"礼来","ABBV":"艾伯维公司","REGN":"再生元制药公司","GILD":"吉利德科学","MRK":"默沙东","HOOK":"Hookipa Pharma Inc"},"source_url":"https://www.cnbc.com/2021/05/31/3-stocks-to-watch-as-asco-conference-gets-underway-.html","is_english":true,"share_image_url":"https://static.laohu8.com/72bb72e1b84c09fca865c6dcb1bbcd16","article_id":"1104481164","content_text":"The annual ASCO meeting begins at the end of the week, a conference that has often provided a tailwind for biotech and pharma names.\nBiotech has been a laggard this year, gaining big in February and March but declining and trading in a choppy range since then.\nBank of America analyst Geoff Meacham identified three companies that could get a positive reception at the meeting.\nThe The American Society of Clinical Oncology meeting will be virtual for a second year, and runs from from June 4 to June 8. Meacham said it is important but ASCO may not provide the pop to stocks it did in other years.\n“ASCO was by far and away the biggest medical conference of the year, and people looked forward to that. And you would have company presentations in front of 30,000 oncologists,” he said. “There would be hundreds of Wall Streeters. You could get a very good handle on what was the buzz of the meeting. SInce it’s virtual, it doesn’t have as much of its charm.”\nBut Meacham said ASCO could still be positive. “You have data that’s brand new and that could lead to approvals and some very good products,” he said.\nMeacham said he’s still positive on biotech despite its lackluster performance. He especially likes mid-cap biotech.\n“We’ve been pretty positive on the group. Recognizing that drug pricing has been a little bit of a cloud over the past couple of years, and 2021 is no different,” said Meacham. “But when you look at the pipeline, the midcap biotech pipeline looks fantastic.”\nThe pipeline in big pharma is got but not as robust. “For the most part, it’s singles and doubles. But not surprisingly, midcap biotech has some home run potential but with more risk. That’s what drives the industry - the innovation and new therapies - and that’s why we’re still positive.”\n\nThe IBB iShares NASDAQ Biotech ETF gained 0.4% last week, but it is up just 0.3% year-to-date. The widely followed IBB was down 1.7% for the month of May.\nMeacham identified three companies that could get a positive reception at the ASCO meeting. Bank of America has a buy rating on all of them. One of those is big pharma Bristol-Myers Squibb.\n“Bristol is probably one of the winners,” he said. The company’s anti-LAG-3 antibody relatlimab melanoma treatment has been in development and there will be data from a large phase 3 trial. He said the product was used with its Opdivo, and could have a better safety profile than the current treatment of Opdivo combined with Yervoy. He does expect Opdivo and Yervoy to maintain the lead share of the market going forward.\nBig cap biotech Amgen is presenting on its lung cancer drug Lumakras, which received Food and Drug Administration approval Friday. The drug was approved to treat lung cancer patients with a genetic mutation known as KRAS. The approval came sooner than expected and sent Amgen shares up more than 1.1% Friday.\nHe said it could be combined with other therapy, like Opdivo. “That two drug combination could be really profound,” he said.\nBiotech company Seagen is going to present on its Padcev treatment for bladder and kidney cancer, launched last year. “This is an update of existing data,” he said. The data shows patients live longer.\nThe study is a small phase 2 trial, but there is another larger phase 3 trial that combines the therapy with Merck’s Keytruda.\nOther companies with data to be presented at ASCO include Eli Lilly,Merck,Regeneron,Hookipa,AbbVie, and Gilead.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"}],"hasMoreComments":true,"newsSizeData":{"likeSize":147,"commentSize":36,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false}}